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Chapter 1: Abstract 
 
Female genitourinary schistosomiasis (FGS) has been associated with increased HIV 
susceptibility, presumably through lesions secondary to parasitic eggs in situ in the female 
genital tract.  We determined the prevalence of FGS infection by real-time PCR (indicative of 
local involvement of parasitic eggs in the genital mucosae) and sero-prevalence of 
schistosomiasis (indicating prior exposure to parasitic infection) in HIV-uninfected KZN 
women (n=383) who had participated in the CAPRISA004 trial. The hypothesis for this study 
was that FGS, and genital tract inflammation are risk factors for HIV-acquisition.  DNA PCR 
was used to confirm the presence of FGS, ELISAs were used for detection of Schistosoma 
spp IgG and multiplex technology was used to detect genital tract cytokines in the 
cervicovaginal lavages (CVLs).  The median age of the women in this study was 23 years 
(range 20-26 years).  Of the 383 HIV negative women, 52/383 (13.8%) became HIV-infected 
by study exit with an HIV incidence rate of 9.1 per 100 women-years ( 95% CI: 6.8 – 
11.9).  Nine of 383 (2.3%) women had a positive DNA PCR for Schistosoma spp indicative 
of prevalent genital schistosomiasis.  Of these 9 women, 4/9 (44%) acquired HIV infection by 
study exit with a 4.0 times increased risk for HIV-infection (OR of 4.05- 95% CI 1.8-8.9, 
p=0.01) than PCR-negative women. Schistosoma haematobium, the endemic species in KZN 
has high sequence homology with S. mansoni antigen which was used to detect IgG in the 
plasma samples. Of the 383 plasma samples from study entry, 21/383 (5.5%)  and 19/383 
(4.96%) of study participants had detectable levels of IgG to S. mansoni at study exit. . Only, 
MCP-3, a chemokine was significantly higher in FGS+ compared to FGS- healthy HIV 
negative women. Genital tract pro-inflammatory cytokines at study exit were significantly 
higher in FGS-HIV+ women for IL-1β, MIF, IL-1A & IL-6 compared to FGS-HIV- women 
(p<0.0001, p=0.0014, p=0.0088, p=0.0069 respectively). Anti-inflammatory cytokine data in  
FGS-HIV+ women showed higher median levels of IL-1RA & IL-2RA compared to FGS –
HIV- women (p<0.0001 & p=0.0012 respectively). Mixed responses of both pro and anti-
inflammatory cytokines in the presence or absence of FGS may be an indication that HIV 
infection is driving these signatures and causing dysregulation. The presence of parasite DNA 
in the genital tract was significantly  associated with increased risk for HIV acquistion. Taken 
together, these results highlight the importance of understanding the complex interplay of 
parasitic infections, and host immunity as potential risk factors for HIV acquistion in regions 
with high HIV and parasite burden. 
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Hypothesis 
 
Female genitourinary schistosoma infection increases risk to HIV-1 acquisition, possibly by 
causing local lesions in mucosae, thereby increasing inflammatory responses in the female 
genital tract.  The role of genital tract and systemic inflammation during Schistosoma spp 
infections in determing HIV risk in women is not completely understood.  Therefore, this 
study sought to investigate the prevalence and incidence of Schistosoma spp infections by 
identifying the presence of schistosomal DNA and Schistosoma spp antibodies in women 
who were part of the placebo arm of the CAPRISA 004 trial. Specifically, the hypothesis was 
that women with detectable DNA specific to this parasitic infection in the genital mucosae 
had elevated genital cytokine responses compared to women who did not show evidence of 
infection, placing these women at higher risk for HIV acquisition. 
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Chapter 2: Literature review 
 
2.1.1: Worldwide prevalence of Schistosomiasis 
 
Schistosomiasis or bilharziasis is a waterborne parasitic infection caused by three main 
species of worms: Schistosoma mansoni, Schistosoma haematobium and Schistosoma 
japonicum. Schistosoma spp infections are a major global health problem; tropical and sub-
tropical countries (Saathoff et al., 2004), at least 200 million individuals may be infected 
worldwide with ~90% of these cases (~180 million) occurring in sub-Saharan Africa (SSA) 
(WHO, 2012, WHO, 2015). In SSA, the two main species responsible for infections are S. 
mansoni and S. haematobium, accounting for 280 000 infections that occur every year 
[reviewed by (Lustigman et al., 2012)]. Schistosoma mansoni and S. haematobium in SSA are 
the species that cause both hepatic-intestinal and urinary schistosomiasis [Figure 2.1]. 
 
 
Figure 2.1: Geographical distribution of schistosomiasis. Sub-Saharan Africa has the 
majority of both hepatic-intestinal and urinary parasitic infections caused by Schistoma spp. 
(Center for Disease Control and Prevention, 2016). Illustration adapted in November 2016, 
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from http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-
travel/schistosomiasis.  
 
 
Schistosome infections have been the cause of many deaths worldwide, with SSA bearing the 
major burden of infection with attributable deaths (Figure 2.2). 
 
 
 
Figure 2.2: Burden of disease and deaths caused by schistosomiasis. Disease burden in 
Africa is highlighted by its disproportionate size relative to other continents. High prevalence 
of schistosoma infections (indicated in red) exist in SSA, with medium prevalence (indicated 
in orange and yellow) occurring in North African countries and low prevalence (indicated in 
green) in South America & Eastern countries . Figure shows deaths that occurred due to 
schistosomiasis in 2002 (0.08%), with an average of 7 deaths per million people (figure 
adapted in January 2015 from www.worldmapper.org).  
 
Schistosomiasis is recognized as a disease of poverty, being highly preventable and curable 
(Olds and Dasarathy, 2001). Poor sanitation remains a key driver of this disease, particularly 
where people come into contact with human faeces or urine-contaminated water supplies 
(Center for Disease Control and Prevention, 2012). It has been proposed that women are at a 
higher risk of contracting this parasitic disease than men because they typically carry out 
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domestic chores, including washing clothes, which may increase their exposure (Mutengo et 
al., 2014). 
 
2.1.2 Prevalence of schistosomiasis in South Africa 
 
Surveillance for schistosomiasis in South Africa is not routine, seroprevalence has been 
reported to be high, ranging from 71 to 100% in Limpopo and KwaZulu-Natal (KZN) 
provinces (Moodley et al., 2003). The prevalence of urinary schistosomiasis in KZN was 
7.2% in 2004 [reviewed in (Johnson and Appleton, 2005)], however no more recent studies 
have been conducted on the parasitic burden in this province. Given the high sero-prevelence 
rates, schistosoma remains a major but neglected public health concern in South Africa, 
particularly in KZN (Kjetland et al., 2012). 
 
2.1.3 Converging epidemics of HIV and helminth infections  
 
It has been suggested that helminth infections impact negatively on the HIV epidemic 
(Mkhize-Kwitshana et al., 2011). In 2013, South Africa had ~6.4 million (range 5.8-6.1 
million) individuals infected with HIV, with KZN province having a substantial portion of 
these individuals [~1.2 (1.1-1.3) million individuals] (WHO, 2013). Furthermore, women are 
at over two-fold higher risk to acquire HIV than males in South Africa  (CDC, 2014), 
(Abdool Karim et al., 2010a). The majority of HIV infections that occur in South Africa are 
sexually transmitted (Abdool Karim et al., 2010b). Like schistosomiasis, KZN also has the 
highest prevalence of HIV (16.9%) than other provinces in South Africa (Shisana and Rehle, 
2014).  
 
Since cervicovaginal inflammation has been shown to significantly increase women’s risk for 
acquiring HIV infection (Masson et al., 2015) by ensuring higher numbers of HIV target cells 
being recruited to the genital tract (Anahtar et al., 2015), convergence of the HIV and 
Schistosoma spp epidemics in KZN may predispose women to HIV infection and is therefore 
important to investigate. Further recent evidence shows that systemic immune activation 
induced by helminth infections through broad T cell activation can lead to significantly 
increased susceptibility to HIV (Kroidl et al., 2016) and HPV infection (Gravitt et al., 2016). 
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2.2 Schistosoma life cycle 
 
Schistosomes belong to an ancient lineage of the animal kingdom, known as Platyhelminthes. 
They occur in both parasitic and free-living forms (reviewed (Rollinson and Johnston, 1996). 
Snails are the intermediate hosts for schistosomes and are an essential component of the 
parasitic life cycle. Three major species that are responsible for causing Schistosoma 
infection are S. haematobium (usually but not confined to causing urinary schistosomiasis), S. 
mansoni and S. japonicum (usually but not confined to causing intestinal schistosomiasis). 
Even though the transmission routes are similar for the various species, they can be 
distinguished from each other based on egg morphology and also on the main anatomical 
sites they locate to and cause pathology (Pitchford, 1965). S. haematobium has a terminal 
spike on its ova whereas S. mansoni has a lateral spike.  S. japonicum has a round or pear-
shaped ova that are pale yellow as shown in Figure 2.3. 
 
 
 
Figure 2.3: Parasitic life cycle of schistosoma species. Schistosoma cercariae penetrate skin 
of the host and cercariae lose their tails, forming schistosomules. These circulate in the host 
bloodstream to the liver where they mature into adult worms.  Paired adult worms then move 
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to mesenteric vessels of the bowel or rectum, or to the venus plexus of the bladder and egg 
laying occurs through this passage. Eggs are shed either through the urine or through the stool 
of the human host.  The eggs hatch in the water to release the miracidia, which then penetrate 
snails as their intermediate hosts, these miracidia then develop into sporocysts. Through 
several cycles, these mature into cercaria in order to complete the life cycle of the worm 
(Center for Disease Control and Prevention, 2012). Illustration adapted in January 2015, from 
http:// http://www.cdc.gov/parasites/schistosomiasis/biology.html 
 
Schistosoma infection occurs when free-swimming larvae, called cercariae, penetrate the skin 
of individuals who come into contact with contaminated water (reviewed by (Rollinson and 
Johnston, 1996). The local site at which the cercariae penetrates the human host skin can lead 
to a condition called “swimmer’s itch” (reviewed by (Rollinson and Johnston, 1996) which 
lasts for one week (Verbrugge et al., 2004). The cercariae otherwise pass unnoticed into the 
body and migrate via blood and lymph systems through the lungs to vessels of the liver 
(Harvie et al., 2007). In the liver of their host, worms pair-up, mature and move to preferred 
egg laying sites to complete their life cycle.  
 
Sites of infection and manifestation of pathology are specific to the particular schistosoma 
species causing the infection. S. mansoni is known to cause intestinal schistosomiaisis 
(reviewed by (Rollinson and Johnston, 1996), whilst S. haemotobium causes mainly urinary 
or genital schistosomiasis (Kleppa et al., 2014). Often the schistosomules (immature form of 
schistosome after entry of the hosts blood vessels) migrate via the bloodstream and ultimately 
manifest in the bladder (Kjetland et al., 2012). Eggs are deposited into the tissue and may be 
passed through the stool or urine to carry on their life cycle depending on the site of infection 
(Figure 2.3). 
 
2.2.1 Pulmonary schistosomiasis 
Schistosomes may also migrate to and cause pathology in the lungs of human hosts.  
Pulmonary schistosomiasis is usually associated with miliary mottling or diffuse nodular 
infiltrates, detectable by X-ray (Schaberg et al., 1991). Infection usually develops in people 
residing or travelling in endemic areas (Niemann et al., 2010). Pulmonary schistosomiasis 
occurs 3–8 weeks after infection and symptoms such as fever, headache malaise, myalgia, 
cough, hepatomegaly and peripheral eosinophilia are experienced (Cooke et al., 1999).  
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Granuloma formation in the lungs and fibrosis around the schistosome eggs retained in the 
pulmonary vasculature may cause pulmonary hypertension leading to cor pulmonale, defined 
as abnormal enlargement of the right hand side of the heart caused by lung disease (Niemann 
et al., 2010).   
 
 
2.2.2 Female genital schistosomiasis 
 
Female genital schistosomiasis is defined by the presence of sandy patches visible in the 
lower female genital tract (Figure 2.4), or by microscopic confirmation of S. haematobium 
eggs in genital tissue in situ. In the lower reproductive tract, genital schistosomiasis may 
involve the vulva, vagina, ecto- and endocervix, and bladder, leading to pathogenesis and 
disease.  
 
One mechanism proposed by which genital schistosomiasis symptoms could occur in the 
vagina is through transmission via the urinary tract in the infected individual. During 
urination, the ova are excreted out of the female genital tract  (Kjetland et al., 2012). As the 
ova are excreted through the urine (depending on the load of ova in the urine), these ova can 
become trapped in tissues and be subsequently recognized and surrounded by immune cells 
that may have migrated to the site of ova in the tissues of the lower female genital tract.  This 
results in an inflammatory reaction, which can lead to fibrotic scarring (Willey et al., 2008). 
An alternative mechanism that has been proposed may be spill-over of eggs into the genital 
tract and cervix through blood vessel anastomoses (where two blood vessels reconnect, that 
previously branched out) between the pelvic organs (Figure 2.4). These lesions or sandy 
patches (Figure 2.4B) and abnormal blood vessels in the genital tissue are visible when 
colposcopy is performed (Kjetland et al., 2012).   
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Figure 2.4: Urinary, genital and intestinal tracts of a female with schistosomiasis. (A) 
Diagram showing eggs of the helminth transmitted through the blood vessels anastomoses in 
the pelvic organs to the genital tract. This process results because of the proximity to the 
pelvic organs in the female [reviewed in (Kjetland et al., 2012)].  (B) Colposcopy image of 
the female genital tract from a Schistosoma-infected women, showing (a) homogenous 
yellow sandy patches (sandy areas with no distinct grains), (b) grainy sandy patches (forming 
oblong yellow to white grains, approximately 0.05 0.2 mm in size); (c) abnormal blood 
vessels [also referred to as ‘neo-vascularization’, are pathological convoluted (corkscrew)]; 
and/or branched and uneven-calibered blood vessels that are visible (under 15X 
magnification) on the mucosal surface. They are deeply or superficially situated in the 
mucosa.  Diagnosis for female genital shistosomaisis is often quite difficult to make in the 
absence of colposcopy (Norseth et al., 2014). 
 
Symptoms associated with female genital schistosomiasis, particularly cervical 
schistosomiasis, are non-specific and may be unremarkable.  They may be associated with 
post-coital bleeding, lower abdominal pain or, in more severe cases, menorrhagia, which 
involves additional abnormal bleeding during menstruation (reviewed by (Rollinson and 
Johnston, 1996). Therefore, genital pathology caused by S. haematobium may go unnoticed 
and remain under-reported and under-treated.  Colposcopy is the current gold standard for 
confirming the presence of female genital schistosomiasis (Kjetland et al., 2012). During 
colposcopy, cervical schistosomiasis can appear as cauliflower-like growths which are 
ulcerative, homogenous yellow areas, known as “sandy patches” (Mosunjac et al., 2003).   
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2.2.3 Gastrointestinal schistosomiasis 
 
Some schistosome eggs pass through the wall of the intestine and is the most common 
manifestation and is usually caused due to S. mansoni [reviewed in (Rollinson and Johnston, 
1996)]. Schistosoma mansoni lives in the bloodstream in the portal circulatory system (Pearce 
and MacDonald, 2002). In some rare cases, S. haematobium was the causative agent (Ata et 
al., 1970). Paired adult worms migrate to the mesenteric venules of the bowel/rectum and 
during this process eggs are laid which then circulate to the liver and are shed in stool. In the 
large intestine, the schistosoma ova are mainly distributed in the loose sub-mucosa, and fewer 
in the sub-serosa (which is the layer of tissue between the muscularis and serosa) where there 
is infrequent formation of multiple granulomas (Strickland, 1994). In the gastrointestinal 
mucosa, sandy patches usually occur if the sub-mucosa thickens due to fibrous tissue 
containing large numbers of calcified eggs. The mucosa then takes on a yellow dirty 
appearance (Strickland, 1994). Long term involvement of the gut can lead to bloody 
diarrhoea and abdominal pains (Nour, 2010). Eggs present in the intestinal veins migrate via 
portal blood flow to the liver causing inflammation which results in hepatic enlargement and 
periportal fibrosis (Harvie et al., 2007). 
 
2.2.4 Helminth induced immune responses in humans 
 
Schistosoma infections involve diverse organs and systems in the human host and can 
therefore elicit diverse immune responses. Cytokines are soluble proteins that exert both 
broad and targeted immune responses (Berger, 2000). T helper type 1 (Th1) cytokines are 
known to enhance pro-inflammatory cellular immune responses that account for killing 
intracellular parasites and eliciting autoimmune responses (Berger, 2000). T helper type 2 
(Th2) cytokines control helminth infections, as well as act in allergic responses and enhance 
antibody responses, through the upregulation of IgE and eosinophilic responses typically 
found in atopy (Berger, 2000). 
 
Helminth infections in humans are generally associated with Th2 immune responses (T-cells 
that produce 1L-4 and IL-13) (Adachi et al., 2014). In the early phase of infection, Th1 
immune responses are present while Th2 immune responses dominate after oviposition 
(deposition of eggs by Schistosoma spp) (Figure 2.5) (Adachi et al., 2014).  Infection with 
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parasites (such as the schistosoma species) usually result in the production of interleukin 
(IL)-4, IL-5, IL-9 and IL-13, typically associated with Th2-type responses (Adachi et al., 
2014).  These Th2-associated cytokines mediate immune responses by inducing 
differentiation of T cells, production of IgE and IgG by activated B cells, and recruitment and 
activation of innate effector cells (Maizels et al., 1993).  
 
 
 
Figure 2.5:  Th1- and Th2-immune response phases during Schistosoma infection.  Th1 
immune responses are initiated during the initial acute phase of infection, and wane after 5-6 
weeks. Th2-immune responses emerge at 6 weeks post infection, where they dominate and 
reach a steady state into the chronic stage of infection [adapted from (Pearce and MacDonald, 
2002)]. 
 
2.2.5 Helminth immune modulation increases susceptibility to other diseases 
 
Helminth infections are thought to impair host immune responses to many diseases, because 
they skew host immunity to Th2 rather than Th1-type responses typically associated with 
protection from infectious diseases (Chen et al., 2012, Horsnell and Brombacher, 2008, 
Horsnell and Brombacher, 2010).  Parasitic infection play a role in altering susceptibility to 
autoimmune disorders and allergies, (Santiago Hda et al., 2015) through increased IgE and 
eosinophilic responses (Huang et al., 2015). This suggests that parasitic infection impairs host 
immune function through ongoing antigenic stimulation in various biological compartments 
(Bashir et al., 2002). Infection by helminths are known to increase the susceptibility for HIV 
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acquisition (Kroidl et al., 2016) and HPV infection (Gravitt et al., 2016)due to the systemic 
immune activation caused by these parasites. 
 
 
 2.2.6 Schistosomiasis as a risk factor for HIV acquisition 
 
Understanding mucosal risk factors in the female genital tract is critical for understanding 
HIV susceptibility. Female urogenital schistosomiasis (FUS) could pose as a risk factor for 
HIV acquisition (Downs et al., 2011). A few epidemiological studies have highlighted 
increased risk for HIV acquistion in areas highly endemic for schistoma parasites (Downs et 
al., 2011, Kjetland et al., 2006, Ndhlovu et al., 2007). Furthermore, female genital 
schistosomaisis along with sexually transmitted infections (STIs) are associated with an 
increased susceptibility to HIV-1 acquisition, presumably because they create lesions in the 
genital mucosa allowing entry of the virus (Kleppa et al., 2014, Mbabazi et al., 2011). 
 
Immunological studies have provided mechanistic insight into the relationship between 
schistosomiasis and risk for HIV acquisition. In addition to causing lesions in the genital 
mucosa, schistosomiasis also appears to increase HIV susceptibility through inducing chronic 
immune modulation (Secor et al., 2003). The various mechanisms put forward show that 
there is a bias towards the Th2 immune response and at the same time there is a 
downregulation of the Th1 response which may then increase the susceptibility to HIV 
infection (Pearce et al., 1991). This is further supported by evidence that CD4+ T-cells with a 
Th2 phenotype rather than a Th1 phenotype were more likely to be HIV-infected (Maggi et 
al., 1994), and in the presence of a background of a S. mansoni –HIV co-infection, these Th2 
CD4+ T-cells are preferentially depleted [reviewed in (Mbabazi et al., 2011, Mwinzi et al., 
2001)]. In addition, S. mansoni –HIV co-infection also depletes HIV specific CD8 T-cell 
responses further compromising immunity (McElroy et al., 2005). However, despite the 
decline of CD4+ and CD8+ T-cells with S. mansoni-HIV co-infection, upregulated surface 
expression of CCR5 and CXCR4 (major co-receptors that facilitate the entry of HIV into 
CD4+ T-cells) on target cells increase HIV infection of cells and replication (Secor et al., 
2003). However praziquantel treatment in Schistosoma-HIV co-infected individuals have 
been shown downregulate CCR5 and CXCR4 expression (Secor et al., 2003), suggesting that 
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such treatment may indeed impact on the spread of HIV in high prevalence areas where HIV 
and Schistosoma spp prevail.  
HIV-1 and STIs remain a public health challenge and the interplay between these and the 
presence of female genital schistosomiasis remains largely undefined. The CAPRISA 002 
study focused on women that were in the acute phase of HIV infection and aimed to 
characterize the viral set point, clinical progression of subtype C infection and identify host 
genetic, viral and immune factors that may predict disease progression.  In the CAPRISA002 
Acute Infection cohort, Mlisana et al., (2012) demonstrated that both symptomatic and 
asymptomatic STIs resulted in increased concentrations of several soluble cytokines at 
cervicovaginal lavages (CVLs). These inflammatory cytokines were independent predictors 
of HIV acquisition in prospective follow-up, after accounting for multiple comparisons, 
including: IL-6 (HR 1.25, 95% CI 1.05-1.50), IL-1β (HR 1.28, 95% CI 1.07-1.54), IL-8 (HR 
1.39, 95% CI 1.04-1.87) and sCD40L (HR 1.45, 95% CI 1.02-2.07; per 1 log10 pg/ml 
increase in cytokine concentration. 
 
Pre-infection, Masson et al. (2015) further showed that in women with genital inflammation 
there was a >3.0 fold increased risk for HIV acquisition compared to women with no genital 
tract inflammation. Inflammation was defined as having 5 of 9 key pro-inflammatory 
cytokines (MIP-1α, MIP-1β, IP-10, IL-8, MCP-1, IL-1α, IL-1β, IL-6, and TNF-α) elevated in 
the genital tract. Genital tract inflammation, defined as being in the highest quartile for any 
combination of 5 of 9 inflammatory cytokines (including IL-1α, IL-1β, TNFα, IL-6, IL-8, IP-
10, MCP-1, MIP-1α, and MIP-1β) was associated with a 2.9-fold increase in risk of HIV 
acquisition overall.  
 
Kedzierska and Crowe (2001) reported that Th1 cytokines (IL-2 and IFNγ) are generally 
suppressed during HIV infection, whilst Th2 cytokines (IL-4 and IL-10) are elevated. IL-10 
treatment inhibited HIV replication in monocytes (Masood et al., 1994). The interplay 
between the Th1 and Th2 responses in the presence of genital inflammation due to STIs and 
parasitic infection remains poorly understood.  
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2.2.7 Anatomy and physiology of the female genital tract 
 
The female reproductive tract has distinct anatomical compartments composed of the upper 
tract including the endocervix and uterus, and the lower tract including the ectocervix and 
vagina.  The upper genital tract is a predominantly sterile environment, whilst the lower 
genital tract comprises a complex biome of commensal flora, including lactobacillus species, 
and sometimes pathogens (Huszar, 1991).  Lactobacillus species promote vaginal health by 
producing lactic acid that lowers pH that is inhospitable to many non-commensal bacteria. 
Predominance of Lactobacilli is negatively correlated with bacterial vaginosis (BV), a 
dysbiotic outgrowth of anaerobic bacteria (Lamont et al., 2011).  Lactobacilli in the genital 
tract also produce hydrogen peroxide (H2O2), antibiotic toxic hydroxyl radicals, bacteriocins 
and probiotics (Lamont et al., 2011) which have antimicrobial activity.   
 
The female vaginal tract has two types of epithelia: type I and type II. The type I epithelium 
of the endocervix is comprised of the simple columnar epithelium while the type II 
epithelium of the vagina and ectocervix mucosa comprises non-keratinized stratified 
squamous epithelium. This forms a natural barrier against pathogens (Rose et al., 2012).  The 
region at which the two types of epithelia transition is known as the transformation zone, and 
is thought to be particularly susceptible to infections including human papillomavirus (HPV) 
and HIV. The sub-mucosa lies beneath the epithelium, which is the site of innate and 
adaptive immune cells.                                                                                                        
 
 
 
2.2.8 Innate immune responses in the female genital tract 
 
At mucosal barriers to the outside world, one of the first barriers against infection is mucus, 
which acts as a defense barrier for most invading pathogens. The lower reproductive tract in 
women is lined with mucus which covers the luminal surface (Iwasaki, 2010). In an aqueous 
matrix, the thick consistency of the mucus is due to its constituents such as glycoproteins and 
gel-forming mucins (Pudney et al., 2005).  Goblet cells are responsible for producing and 
secreting mucus in type I epithelia, whilst local mucus-secreting epithelial cells produce 
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mucus in type II epithelia (Pudney et al., 2005).  In the lower reproductive tract, goblet cells 
are found in the endocervical canal. Vaginal mucus also contains other immune defense 
molecules such as antibodies, antimicrobial peptides and enzymes.   
 
In the lower reproductive tract, a variety of immune defense molecules [such as complement 
proteins, antimicrobial peptides which includes mannose binding lectins (MBLs) and 
secretory leukocyte protease inhibitors (SLPI)] are responsible for protecting the vagina 
against invading pathogens [reviewed in (Iwasaki, 2010)]. MBLs bind to carbohydrates on 
various, parasites, pathogens & bacteria. Complement proteins have been detected in 
cervicovaginal secretions, providing first-line defence against infectious agents colonizing the 
lower region of the reproductive system (Bulla et al., 2010). These molecules prevent 
interaction between the pathogens and vaginal epithelium by directly combating and killing 
foreign pathogens. These antimicrobial compounds are constantly produced by vaginal 
mucosal epithelial cells, and neutrophils present in the sub-mucosa and cervix [reviewed in 
(Iwasaki, 2010)]. Vaginal fluid also contains defensins and lysozyme that contribute to 
antimicrobial defense (Valore et al., 2002). 
 
The presence of commensal flora at the vaginal mucosa has recently been shown to be central 
in maintaining genital health in women [reviewed (Spurbeck and Arvidson, 2011)]. 
Commensal bacteria typically found in the lower reproductive tract include Lactobacillus, 
Corynebacterium and Peptostreptococcus spp., with Lactobacillus species being the most 
prevalent [reviewed in (Spurbeck and Arvidson, 2011)].  
 
 
Innate immune cells that provide protection against pathogens in the vaginal mucosa include 
macrophages, dendritic cells (DC), langerhans cells and γδ T cells [reviewed in (Milligan, 
1999)].  Additional innate immune cells are recruited to the site of pathogen invasion, which 
include natural killer cells (NK cells), neutrophils, monocytes and plasmacytoid DCs (pDCs) 
(Pudney et al., 2005). Dendritic cells patrol and protect the vaginal environment through 
phagocytosis [reviewed in (Savina and Amigorena, 2007)]. Upon DC activation (Figure 2.6) 
by an invading pathogen, they migrate to the draining lymph node where they prime naïve T 
and B cells, initiating an adaptive immune response [reviewed in (Iwasaki and Medzhitov, 
2004)]. 
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Figure 2.6: Innate immune responses at vaginal mucosa. a) Innate immune cells such as DCs 
and macrophages patrol the vaginal lumen during a relaxed state whilst the epithelial layer of 
the vaginal lumen is still intact (no invading pathogen). b) Microabrasions of the epithelial 
layer occurs upon invasion of antimicrobial peptides, viruses and pathogens. Antigen 
presentations by DCs that detect pathogens occur and migration to the lymph node takes 
place. Infected macrophages release type I IFNs, whilst NK cells and monocytes are also 
released from the blood stream [taken from (Iwasaki, 2010)]. 
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2.2.9 Adaptive immune responses in vaginal mucosa to pathogens 
 
Upon detection of an invading pathogen, antigen presenting cells such as DCs take up foreign 
antigen at the mucosal surface, migrate to the lymph nodes and present to naïve CD4
+
 and 
CD8
+
T cells (Lee et al., 2009). Activated CD8+ T cells, which are also known to be 
cytotoxic, migrate to the site of infection and kill virus-infected cells expressing cognate 
antigen (Altfeld et al., 2002). CD4+ Th1 effector cells have the ability to protect against 
viruses by migrating to the mucosa and secreting interferon gamma (IFN-γ) (Iijima et al., 
2008). Following infection, Th2 cells induce class switching (biological process that changes 
B cell’s immunoglobulin production from one type to another) in B cells, leading to antibody 
production (Toellner et al., 1998). Antibody-producing B cells constitute an important arm of 
the adaptive immune response in the genital mucosa. Sexual transmission of pathogenic 
viruses, parasites and bacteria are the most common causes of infection in the genital tract, 
with HIV being the most prevalent sexually-transmitted viral infection among women in SSA 
[reviewed by (Quinn and Overbaugh, 2005)].  
 
Although less studied and less common, parasitic infection of the female genital tract, 
causing genital inflammation, could lead to an increased susceptibility to HIV-1 infection 
(Feldmeier et al., 1998). 
 
2.2.10 HIV transmission across the vaginal mucosal barrier 
 
The vaginal epithelium is a multi-layered thick, mucus-coated barrier that is almost 
impenetrable to invading viruses, bacteria and parasites. Lesions caused by female genital 
schistomomiasis provides opportunity for HIV to enter the mucosal barrier through these 
microabrasions and gain access to target cells in the submucosa, including CD4+ T cells, 
DCs, langerhans cells and macrophages [reviewed in (Magaisa et al., 2015)]. About 80% of 
new HIV infections are caused by a single HIV variant following vaginal transmission, 
usually referred to as a “bottleneck” (Keele et al., 2008).  
However, in the presence of vaginal microabrasions, multiple viral strains may have a chance 
to permeate and enter the genital mucosae (Iwasaki, 2010). 
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Several mechanisms have been proposed for how HIV is able to cross the mucosal barrier 
and gain access to CD4+ target cells, including transcytosis of the epithelial layer, or entry 
through micro-lesions or microabrasions in the epithelial barrier [Figure 2.7; reviewed by 
(Shattock and Moore, 2003)]. Infection of Langerhans cells within the epithelium which can 
transmit virus to CD4+ target cells in the submucosa is another hypothesized method of 
transmission (Miller and Shattock, 2003). The transformation zone between the multi-layered 
squamous epithelia of the vagina and single-layered columnar epithelium in the endocervix 
was previously thought to be the most susceptible point for HIV infection because of the 
presence of high numbers of potential target cells like the CD4+ cells in this region (Carias et 
al., 2013). More recently, Stieh et al. (2014) showed that HIV also caused infection of the 
upper reproductive tract. 
 
 
 
Figure 2.7: Mechanisms by which HIV crosses the vaginal mucosal epithelium [taken from 
(Shattock and Moore, 2003)]. Left figure panel represents HIV crossing the mucosal barrier in 
columnar epithelium (a) infection by HIV with viral RNA integrating into the DNA of host cells, 
(b) transcytosis of HIV virion through mucosal barrier & (c) transmigration of HIV virion that’s 
attached to a macrophage. The right panel of the figure represents the HIV mechanism of entry in 
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stratified epithelium, (d) HIV virions attach to Langerhans cells between the mucosal barriers due 
to (e) physical abrasions that allow HIV entry to occur with ease. As pathogens invade the 
mucosal barrier, dendritic cells come into contact with the viral particles for antigen presentation 
[reviewed in (Neutra and Kozlowski, 2006)].   
 
Recruitment of HIV target cells in the female genital tract under cytokine gradients can 
strongly influence susceptibility to HIV acquisition. Other co-factors including STIs and 
parasitic infections have been associated with increased risk for HIV acquisition (Feldmeier 
et al., 1998). Parasitic infections may cause increased immune activation, particularly in co-
endemic regions where STIs such as HIV and parasites co-exist (Bentwich et al., 1995). 
Helminths that induce systemic immune responses could also alter the local mucosal 
immunity of the genital tract (Witkin et al., 2000).  
 
Infection by Schistosoma spp remains a global challenge. Sub-Saharan Africa has the largest 
burden for both the Schistosoma infections and HIV. In particular, in South Africa, Kwa-Zulu 
Natal has the highest prevalence of HIV infections countrywide and is therefore epicenter for 
HIV. At the same time, KZN is also endemic for Schistosoma spp. and has the highest 
prevalence of this disease countrywide too. This study that was undertaken in two sites 
KwaZulu-Natal therefore focuses on the interplay between these two diseases and explores 
the immunological risk factors for HIV-acquisition in the presence of Schistosoma infection 
in the female genital tract.  
 
The aims of this dissertation were to: 
- Determine the prevalence and incidence of HIV in women with/without Schistosoma spp 
infections, by indentifying presence of schistosome DNA and Schistosoma spp antibodies in 
women who were part of the placebo arm of the CAPRISA 004 trial. 
- Determine the differences in cytokine levels that play a role in genital inflammation in 
women with/without FGS and with/without HIV. This could help determine whether genital 
schistosomiasis influenced inflammation was associated with increased risk of HIV infection.  
Specifically, the hypothesis was that women with detectable DNA specific for parasitic 
infection in the genital mucosae had elevated genital cytokine responses compared to women 
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who did not show evidence of infection placing these women at higher risk for HIV 
acquisition. 
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Chapter 3: Methodology 
3.1 Study design and population  
This study was a retrospective study of 383 women from the placebo arm of the CAPRISA 
004 1% tenofovir micobicide gel trial (Abdool Karim et al., 2010a). Participants for the study 
were from both a rural community (Vulindlela, Kwa-Zulu Natal) and an urban community 
(eThekwini Clinic, Durban).  All women consented to the study.  This sub-study included 
specimens from two time-points for each women: study entry time-point (3 months post-
enrollment) and study exit, with an average period of 3 years between the study entry and the 
study exit time-points. Cervicovaginal lavage (CVL) supernatants, CVL pellets and anti-
coagulant dextrose plasma (ACD) samples were selected from both time-points for this sub-
study.   
 
3.2 Ethical considerations 
The CAPRISA 004 trial, which assessed the safety and effectiveness of the vaginal 
microbicide 1% Tenofovir gel (Abdool Karim et al., 2010a) was approved by the Biomedical 
Research Ethics Committee (BREC 111/06).  This sub-study underwent expedited ethics 
approval (BREC 333/13).  A copy of the original ethics approval letter and expedited BREC 
approval letter for the sub-study are attached as Annexure 1 (Appendix). 
 
3.3 CVL collection and processing 
CVLs were obtained and processed as previously reported (Bebell et al., 2008, Mlisana et al., 
2012). A volume of 5ml of sterile PBS was used to irrigate and repeatedly bathe the cervix.  
The pooled cervicovaginal fluids that were aspirated from the vaginal vault using a sterile 
plastic bulb pipette were dispensed into sterile conical tubes and transported on ice to the 
laboratory for further processing.  CVLs were centrifuged, and the supernatant was stored at 
−80°C. CVL samples were not collected from menstruating participants, for whom sampling 
was postponed to the following week. 
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3.4 Plasma preparation 
Whole blood collected into ACD tubes were spun down at 800 x g for 30min for the 
processing and storage of the ACD plasma samples. After centrifugation, the ACD plasma 
was pipetted out and stored at -80°C until further use. 
 
3.5 HIV screening and testing 
At each study visit of the CAPRISA 004 trial, two HIV rapid tests [Determine HIV 1/2 
(Abbott Laboratories, Illinois, USA) and Uni-Gold Recombigen® HIV test (Trinity Biotech, 
Wicklow, Ireland)] were performed for each participant to confirm their serostatus. Study 
participants with concordantly positive, discordant or indeterminate results were assessed for 
possible seroconversion by means of two separate RNA PCRs (Roche Cobas Amplicor HIV-
1 Monitor v1.5, Roche Diagnostics, Branchburg, New Jersey, USA), approximately one week 
apart. When HIV seroconversion was confirmed, use of the microbicide or placebo product 
was discontinued and women were enrolled in local AIDS treatment services, including the 
CAPRISA AIDS Treatment Program which provided free antiretroviral therapy for HIV 
infected participants. 
 
3.6 DNA isolation: Template for downstream Real-time PCR 
DNA for real-time PCR was isolated from all CVL pellet samples using the MagNA pure 
isolation kits (Roche, Germany).  Volumes of 50μl of reconstituted cervical pellets per 
sample were aliquoted into 32-well cartridges (Roche, Germany).  According to the 
manufacturer’s instructions, the samples were lysed with lysis buffer, followed by a series of 
wash and precipitation steps with ethanol-based wash buffers using an automated extraction 
method involving the use of the MagNA pure 32 (Roche, Germany) for the extraction and the 
isolation of the DNA.  The DNA was then eluted in 100μl of elution buffer that was supplied 
in the kit and was stored at -80
o
C until utilized.  The concentration of DNA was quantified 
using the NanoDrop 2000 UV-Vis spectrophotometer (Thermo Fischer Scientific, USA) and 
only the DNA samples with a OD260/OD280 ratio of 1.8 were used. The DNA samples were 
then standardised to 1μg of DNA for each sample and for downstream use in real-time PCR 
amplification. 
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3.7 Preparation of S. mansoni DNA for PCR positive control  
In order to verify the presence of the parasite in the clinical isolates of the DNA samples from 
the participants in this sub-study we amplified a region of Schistosome genome common to 
both S. mansoni and S. haematobium. This allowed the use of cercarial S. mansoni DNA as a 
postive control. Total DNA was extracted manually from the cercariae of S. mansoni, 
(obtained from the Division of Immunology, IDM, University of Cape Town) according to 
the manufacturer’s instruction using QIAamp DNA mini kits (Qiagen, USA).  This cercarial 
DNA was used as a positive control for the real-time PCR assay when screening for the 
presence of both S. haematobium and S. mansoni DNA. 
 
3.8 Primer Design, cycling conditions and Real-time amplification of target 
schistosomal DNA 
Primers are short nucleic acid sequences that serve as a target specific starting point for PCR 
or DNA replication processes. Specific primers Ssp48F and Ssp124R (Kjetland et al., 2009) 
were designed and synthesized to detect a target region common to both Schistosoma species 
(Roche, Germany) and were validated in the Hasso-Plattner Laboratory at the HIV 
Pathogenesis Programme laboratory, University of KwaZulu-Natal.  Oligonucleotides for 
Ssp48F &Ssp124R shown below in table 3.1 were used to amplify the 77-base pair (bp) 
fragment of the internal transcription spacer (ITS), homologous to both S. haematobium and 
S. mansoni species from DNA extracted from the CVL pellets. The ITS is the DNA spaced 
between small sub-unit ribosomal RNA (rRNA) and large sub-unit rRNA. 
Table 3.1: Primer sequences 
Specific primers Sequence 5’- 3’ 
 
Ssp48F  5′-GGT CTA GAT GAC TTG ATY GAG ATG CT-3′ 
Ssp124R 5′-TCC CGA GCG YGT ATA ATG TCA TTA-3′ 
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3.9 Real-time polymerase chain reaction for amplification of schistosomal DNA  
Real-time PCR was performed using the Light Cycler LC 480 (Roche, Germany) to detect 
Schistosoma spp. DNA in the CVL pellets from genital samples obtained through cervico-
vaginal lavage. Samples that tested positive for schistosome DNA in the pellet of the CVLs 
were defined as women who were FGS PCR positive for the purposes of this study. 
Furthermore in this study, women that were found to be schistosome DNA PCR positive in 
their CVL do not necessarily have FGS and not all women that have FGS would have tested 
positive by PCR for schistosome DNA in the CVL due to the insensitivity of the genital tract 
PCR (Kjetland et al., 2009, Randrianasolo et al., 2015).   Cycling conditions used were as 
follows: 95
o
C for 5 minutes, 95
o
C
 
for 30 seconds, 60
o
C for 30 seconds and 72
o
C for 30 
seconds with a total of 55 cycles. 
Each PCR reaction contained 10μl according to the Master mix reagents and volumes are 
shown below in table 3.2. Each of the DNA samples were run in in duplicate on a 96-well 
real-time PCR plate purchased from Roche.  Each 96-well plate for PCR was run with a 
positive and a negative control.  SYBR green was used as an intercalating fluorescent dye to 
detect the presence of double stranded DNA amplicons which would represent a positive 
result.  In addition, the melting temperature of 81.2
o
C, or within range of 1
o
C when compared 
to the melting temperature of the positive control (81.2
o
C) were also used to confirm a 
positive PCR result.  Furthermore, samples deemed as positive were also validated on a 1% 
agarose gel to confirm molecular weights of PCR products with the use of a molecular base 
pair ladder (GeneRuler, ThermoFisher Scientific, USA). 
Table 3.2: Real-time PCR reaction volumes (10μl) 
Master mix reagents Master Mix for 1X Master Mix for 100X 
H2O 2.5μl 250μl 
Ssp48F (2.5pmol/μl) 0.25μl 25μl 
Ssp124R (2.5pmol/μl) 0.25μl 25μl 
SYBR green 5μl 500μl 
DNA template 2μl  
 
Real-time PCR in general has specific advantages over conventional PCR. Conventional PCR 
is only measured at the end-point of the assay (plateau), whilst real-time PCR provides data 
 
 
 
39 
 
in the exponential growth phase of a reaction.  Monitoring of melt curves also provides a 
definitive tool for the identification of PCR positive samples when looking at fluorescence 
history and melting temperatures.  In real-time PCR, an increase in reporter fluorescence 
signal (Figure 3.1) is directly proportional to the amount of double-stranded DNA 
(amplicons) present.   
Real-time PCR is therefore quantitative while conventional PCR is largely qualitative.  The 
cleaved probe provides a permanent record amplification of the amplicons.  For real-time 
PCR, there is an increase in dynamic range of detection and does not require post PCR 
processing. 
 
 
 
 
Figure 3.1: RT-PCR principle using universal intercalating dye SYBR green (SG).  As the 
amplification of DNA increases with every cycle, more SG is bound to the double stranded 
DNA, corresponding to a proportional increase in fluorescence [adapted from (Ali et al., 
2011)]. 
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Positive FGS PCR samples were identified by Ct (cycle threshold) values between cycles 15-
30 (Figure 4.1). Cycle threshold values are the fractional cycle of a PCR at which the 
normalized signal of the reporter dye intercepts the threshold. No Ct values were observed for 
Negative FGS PCR samples as the amplification curve (representing the reporter dye of the 
target) of the negative samples did not intercept the threshold.  
 
 
Figure 3.2: Melt peaks of real-time PCR assay showing melting curves temperatures of 
amplicons from nine participants positive for FGS at 81.5°C, thus validating specific PCR 
product. 
Distinct peaks on melt peak plots are representative of the specific targeted PCR product. 
Samples positive for FGS PCR that share the same melting temperature on melt peaks, are a 
clear indication of a specific PCR product. Melting temperature is the temperature at which 
the double stranded DNA product separates into two single strands. Polymerase chain 
reaction products of equal size share common melting temperatures.  In this study, amplicons 
with a melting temperature of 81.5°C (Figure 3.2) were identified as FGS positive PCR 
products and confirmatory tests of the RT PCR products through agarose gel electrophoresis 
were performed in order to further validate that the amplicons were the same molecular mass 
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as that of the positive control. Figure 3.3 represents the 77 base pair FGS PCR amplicons that 
were amplified from the RT PCR reactions of the genital CVL specimens. 
 
Figure 3.3: FGS PCR amplicons (77 bp) performed using a 1% agarose gel as a confirmation 
to the analysis of melt peaks from the real-time PCR data.  The positive control together with 
the molecular weight ladder confirmed the positive results obtained.  NTC = None-template 
control, +C = Positive control, -C = Negative control. 
 
3.10 Cycle sequencing of PCR products and sequencing clean-up reaction prior to 
capillary electrophoresis 
In order to validate FGS PCR amplicons, products were also amplified conventionally [Table 
8.1 & 8.2, (Annexure 2, Appendix)] using Platinum Taq DNA polymerase (Invitrogen, USA) 
and subjected to DNA sequencing.  DNA obtained from the genital CVL samples with the 
same molecular mass and sharing the same melt peaks as the positive control were then 
subjected to DNA sequencing with BigDye v3.1 terminator kits (Applied Biosystems, USA) 
on a 3130XL Genetic Analyzer (Applied Biosystems, USA). Sequencing clean-up reactions 
were performed using the 3M sodium acetate/100% ethanol precipitation with a dilution of 
1:10.  Sequencing was performed on the 3130 XL genetic analyzer (Applied Biosystems, 
USA).  Sequence reaction volumes are shown below in table 3.3. 
 
 
 
 
 
 
42 
 
Table 3.3: DNA sequencing reaction volumes 
Sequencing reagents Master Mix for 1X Master Mix for 12X 
H2O 3.6μl 43.2μl 
BigDye 0.4μl 4.8μl 
5X sequencing buffer 2μl 24μl 
Primer (1.6pmol/μl) 2μl 24μl 
Amplified DNA from CVL 
pellets 
2μl  
 
3.11  Measurement of Schistosoma antibodies by ELISA  
In order to detect the presence of Schistosoma haematobium/mansoni IgG antibodies (as a 
surrogate for exposure to the parasites), qualitative enzyme-linked immunosorbent assays 
(ELISA) were performed on all ACD plasma samples at both study time points.  Due to the 
cross-reactivity of the IgG between the species, S. mansoni antigen used to coat the plates 
was supplied by the Division of Immunology at the University of Cape Town in order to 
detect antibodies to both S. haematobium or S. mansoni species. Plasma samples that were 
obtained from the Division of Immunology at the University of Cape Town, were from 
individuals confirmed to be sero-positive for schistosome infections. These samples were 
used as a positive control for each ELISA, on every plate run in order to validate the assay for 
detecting human IgG responses to S. mansoni antigen. Plasma samples that had no history of 
exposure to helminth infections as well as standard PBS were used as negative controls for 
each ELISA plate. 
 
To pre-coat the ELISA plates (day 1), 96 well Nunc-Maxisorp plates (Nunc Maxisorp™; 
ThermoFisher Scientific, Roskilde, Denmark) were coated with 50μl of 5μg/ml S. mansoni 
antigen and incubated for 3 hours at 37
o
C in a 5% CO2  incubator (ThermoFisher Scientific, 
USA). The antigen used to coat the plates was diluted 1:100 in carbonate buffer (the methods 
for the various wash and blocking buffers for this procedure is attached as Annexure 2). 
Plates were then washed three times with each well containing 200μl of the 1X wash buffer to 
wash off any excess or unbound antigen.  Blocking buffer was then prepared as a 2% milk 
powder in PBS and all wells were then blocked with 200 μl of blocking buffer overnight at 
4
o
C and plates were wrapped in cling wrap to prevent evaporation.    
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On day 2, ELISA plates were washed three times with 200μl wash buffer 24 hours later.  
Dilution buffer (made up using 1% bovine serum albumin PBS solution) was used to dilute 
ACD plasma samples.  Dilutions of the plasma samples (80μl/reaction) were done on V-
bottom 96 well plates, first a 1:50 dilution of ACD plasma sample into dilution buffer, 
followed by 1:5 dilution for a further seven serial dilutions in dilution buffer.  The pre-diluted 
samples (50μl) were then transferred onto the ELISA plates and incubated at 4
o
C overnight 
for further processing.  
 
On day 3, plates were washed three times each with 200μl/well of  wash buffer 24 hours later.  
Secondary antibody, mouse anti-human IgG (Fc)-AP (Clone JDC-10) (Biocom, Biotech, 
Berlin, Germany) was prepared as a 1:1000 dilution in dilution buffer and 50μl was added to 
each reaction well.  Secondary antibodies were alkaline phosphatase conjugated, 4- 
Nitrophenyl phosphate disodium salt hexahydrate (PnP) was used as a substrate to develop 
the colour reaction.  PnP (Sigma Aldrich, USA) was diluted in substrate buffer and 50μl of 
substrate buffer containing PnP was added to each reaction well (Figure 3.2).  Plates were 
incubated at room temperature for 15 minutes to develop, and thereafter reactions were 
stopped with 25μl 1M NaOH once developed. 
 
Plates were then read on the VersaMax ELISA microplate reader plate reader (Molecular 
devices, USA) with the use of Software Max Pro with using the following dual wavelength 
laser modules (LM).  LM1 was set at 405nm and LM2= 492nm as the (reference 
wavelength).  Optical density values > 1.0 in this study were regarded as positive and 
detectable IgG levels for S. mansoni (Vendrame et al., 2001) and was used to confirm that 
participants had exposure to this parasite and had experienced schistosoma infections. 
Participants with S. mansoni IgG O.D values <1.0 were recorded as undetectable in this 
study. 
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Figure 3.4: Principle of indirect antibody ELISA used in this study. Alkaline phosphatase 
conjugated secondary antibody was used, that binds to primary antibody, causing substrate 
PnP to produce a yellow colour (Figure taken from http://www.leinco.com/indirect_elisa, 
March 2015,). 
 
3.12 Measurement of CVL cytokine concentrations by Luminex Multiplex assay 
 
In order to quantify for multiple cytokines in a limited sample volume, a multiplex assay was 
used for the quantitative determination the concentrations of 48 cytokines, chemokines, and 
growth factors in a relatively small volume of CVL sample.  The advantage of using this 
multiplex assay is that a number of analytes can be quantified under the same laboratory 
conditions, decreasing the impact of inter-assay variability.  In this approach, magnetic 
microscopic beads were coated with antibodies specific to cytokines that were bound using a 
chemical process of covalent binding (Figure 3.3).  CVL was then added to the antibody-
coated bead and antibody complex where the respective soluble cytokines present in the CVL 
would then bind.  Fluorescent-labeled reporters are then able to bind to the captured 
cytokines.  Target cytokines were identified and quantified by lasers that detected different 
wavelengths of the fluorescent labeled beads. Prior to the cytokine multiplex assays, each 
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CVL sample (300µl)  was filtered using 0.5ml Corning Costar Spin-X columns, (Scientific 
Group, South Africa), to remove cervical mucus and particulate antigen that could block the 
fluidics of the Luminex plate reader from the soluble protein fraction in which cytokines were 
to be measured. 
 
For this study, the concentrations of the 48 cytokines were determined using two separate 
Bioplex cytokine kits (27 plex and 21 plex kits, Bio-Rad, USA).  The 27 plex kit was used to 
screen for interleukin (IL)-1β, IL-1ra, IL-2 , IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12(p70), IL-13, IL-15, IL-17, basic fibroblast growth factor (FGF), eotaxin, granulocyte 
colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-
CSF), interferon (IFN)-γ, inducible protein (IP-10), monocyte chemo attractant protein-1 
(MCP-1/MCAF), macrophage inflammatory protein (MIP)-1α, MIP-1β, platelet-derived 
growth factor (PDGF)-BB, regulated on activation, normal T cell excreted and secreted 
(RANTES), tumor necrosis factor (TNF-α) and vascular endothelial growth factor (VEGF).  
The 21-plex cytokine kit was used to screen for IL-1α, IL-2Rα, IL-3, IL-12 (p40), IL-16, IL-
18, cutaneous T cell attracting chemokine (CTACK), growth related oncogene (GRO)-α, 
human growth factor (HGF), intracellular adhesion molecule (ICAM)-1, IFN-α2, leukemia 
inhibitory factor (LIF), MCP-3, macrophage colony-stimulating factor (M-CSF), macrophage 
migration inhibitory factor (MIF), monocyte induced by interferon gamma (MIG), beta nerve 
growth factor (β-NGF), stem cell factor (SCF), stem cell growth factor (SCGF)-β, stromal 
derived cell factor (SDF)-1α, TNF-β, TNF related apoptosis inducing ligand (TRAIL) and 
vascular cell adhesion molecule (VCAM)-1. For standards and reagent preparation, samples 
and standards were thawed to room temperature.  The reconstituted lyophilized standard was 
prepared by adding 500μl of standard diluent to form the master standard stock solution. 
Stock solution was then vortexed and incubated on ice for 30 min for use in the serial four-
fold dilution to generate a standard curve.  Samples were prepared during incubation of the 
standard. Nine 1.5 ml eppendorf tubes were labelled (S1-S8) with its respective 
concentrations. Volumes of standard diluent were pipetted into each tube as per manufactures 
protocol. A volume of of 128μl of was then added to S1, which contained 72μl of standard 
diluent.  Fifty microliters (50μl) of the diluted standard from S1 was then transferred into 
tube S2, and thereafter the process was repeated for a serial four-fold dilution in tubes S3 to 
S8 to generate a broad range standard curve. To prepare the beads for the multiplex assay, 
beads were protected from light at all time and adjusted to room temperature prior to useage. 
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Beads were vortexed for 30 seconds before dilution and prepared by adding 5,175μl of assay 
buffer to a 15mL tube. A volume of 575μl of 10X beads was transferred into tube containing 
the 5,175μl (5,175 ml) of assay buffer which was provided in the kit. The diluted beads were 
vortexed for 30 sec and a volume of 50μL was added into each well on the 96 well plate.  The 
wells containing the magnetic beads were then washed twice using the Bio-Plex Pro™ Wash 
Station (Bio-Rad, USA).  The standard dilutions, samples and controls were vortexed gently 
for 1-3 sec and 50μL were added to the appropriate wells.  The plate was then sealed and 
incubated on a shaker at room temperature for 30min at 300 rpm.  During the last 10min of 
the incubation time, 1X detection antibody was prepared by adding 300μL of 10X detection 
antibody to 2,700μL of detection antibody diluent in a 15mL tube. After incubation, the 
sealing tape was removed and the plate was washed three times in order to proceed with the 
addition of the detection antibody to all wells of the 96 well plate. The diluted detection 
antibody was vortexed and 25μL was added into each well.  The plate was covered and 
incubated on a shaker at 300 rpm for 30min at room temperature.  With 10min remaining of 
this incubation time, 1X Streptavidin-Phycoerythrin (PE) was prepared by adding 60μL of 
the concentrated 100X Streptavidin-PE to 5.940μl assay buffer in a 15mL tube.  After 
incubation of the detection antibody, the sealing tape was removed and the plate was washed 
three times. The diluted Streptavidin-PE was vortexed and 50μl were added into each well.  
The plate was sealed and incubated on a shaker for 10min at room temperature.  After 
incubation the plate was washed three times and 125μl of assay buffer was added to each 
well.  The plate then sealed and incubated on shaker at room temperature at 300rpm for 30 
sec.  The plate cover was removed and the plate read using the Bio-Plex 200 Multiplex 
system (Bio-Rad Laboratories Inc, USA). Plates were run on low PMT setttings 
(photomultiplier). 
Data was collected using a Bio-Plex manager software version 6 (Bio-Rad Laboratories Inc, 
USA) and a 5 PL regression formula was used to calculate cytokine concentrations from the 
standard curves. Raw data files were saved as extension RBX files, and thereafter using the 
documents export function on the software,  the files were exported to Microsoft excel format 
(.xml) files containing all the information in the RBX file. 
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Figure 3.5: Illustration of the process of magnetic beads bound with with antibodies, 
followed by soluble cytokine binding from sample with and bound fluorescent labelling 
reporters.  As magnetic beads pass through the flowcell, the red laser identifies the captured 
cytokines bound to the bead whilst the green laser quantifies the cytokines present in the 
sample [adapted from (Nolan and Sklar, 2002)]. 
 
3.13 Statistical analysis 
Generation of dot plots, non-parametric statistical analysis were performed using Graphpad 
Prism V.5. Differences between groups were evaluated using a Student’s t-test or ANOVA, 
as indicated.  Mann- Whitney U and Kruskal Wallis tests were used for unmatched and 
matched comparisons, respectively were used. Bonferroni correction to adjust for multiple 
comparisons was also applied to prevent a Type 1 error and circumvents over estimating 
statistical significance.  P-values less < 0.05 were considered significant.
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Chapter 4: Results 
 
4.1. Description of the cohort 
To evaluate exposure to Schistosoma in the rural and urban parts of Kwa-Zulu Natal, 
this retrospective study included a total of 383 female participants from the placebo 
arm of the CAPRISA 004 1% tenofovir microbicide gel trial (Abdool Karim et al., 
2010a).  Table 4.1 summarizes the clinical characteristics for this cohort. The median 
follow-up time for the 383 women from study entry to study exit was 19.1 months 
(IQR:13.3 to 22.8 months). 
The inclusion criteria for women in the CAPRISA 004 study were as follows: Women 
aged from 18 to 40 years, who were HIV negative, who were sexually active (at least 
twice within 30 days prior to screening), having engaged in unprotected sexual 
intercourse and who were not pregnant were eligible for study enrolment. The median 
age of the women was 22 years (IQR 20-26 years).  Of the 383 women in this study, 
274/383 were from rural Vulindlela (71.5%) and 109/383 were from urban eThekwini 
in the city centre of Durban (28.3%). The majority of the cohort (354/383; 92.4%) had 
a stable partner and all were sexually active and on some form of hormonal 
contraception with 75.9% on Depo Provera and 17.6% on Nuristerate. As a marker of 
socioeconomic status, less than half the women (45.4%; 174/383) had access to 
potable water.  
Most women reported being unemployed (91%). Only 6% of participants owned a 
house. Prevalence of self-reported genitourinary symptoms was low, with 6% 
reporting vaginal itching, 0.01% reporting vaginal burning, and 0.03% had 
genitourinary ulcers. Exposure to helminth infection within the placebo arm of the 
CAPRISA 004 cohort had not previously been investigated. During the trial, 52/383 
of the women in this sub-study became HIV-infected (13.6%), yielding an HIV 
incidence rate of 9.1 per 100 women-years (95% CI: 6.8 – 11.9). 
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Table 4.1: Demographic data of study participants enrolled in the placebo arm of the 
CAPRISA 004 1% tenofovir microbicide gel trial.  
Variables N=383 
  
Age (Median, IQR) 22 (20-26) 
Clinical site (n, %)  
Vulindlela 274 (71.54%) 
eThekwini 109 (28.26%) 
HIV status (n, %)  
HIV negative 331 (86.42%) 
Sero-converters 52 (13.58%) 
Stable partners (n, %)  
No stable partners(s) 29 (7.57%) 
  
Stable partner(s) 354 (92.43%) 
Access to potable water  
 174/383 (45.43%) 
Other Variables N=108 (Data available) 
Employment status  
Unemployed 98 (91%) 
Self-employed 10 (9%) 
Participants owing a house  
Not owning a house 101 (94%) 
Owning a house 7 (6%) 
Symptoms/ Clinical data  
Vaginal Itching 7 (6%) 
Vaginal Burning 1 (0.01%) 
Genitourinary ulcers 3 (0.03%) 
Use of Depo Provera 82 (75.9%) 
Use of injectable Nuristerate 19 (17.6%) 
 
4.2 Prevalence of female genital schistosomiasis in CVL 
Of the 383 HIV negative women screened, 52 (13.6%) became HIV-infected later in 
the study (Table 4.2). Nine of 383 (2.35%) women had detectable FGS DNA in their 
CVLs. Six of these women were from the Vulindlela site, while 3 women were from 
the eThekwini site. Of these 9 women, 3/9 (33%) women had prevalent FGS DNA at 
study entry (at study entry all women were HIV-uninfected). At study exit, 6/9 (67%) 
of these women were FGS PCR+ve. Of these 9 women, 5/9 (56%) acquired HIV 
infection by study exit with 4/9 women (44%) remaining HIV-uninfected despite the 
presence of FGS DNA. These data indicated that women positive for FGS, were 4.0 
times more likely to become HIV-infected than FGS-negative women (OR 4.05- 95% 
CI 1.8-8.9, p=0.01). Forty-eight of the 52 women that sero-converted in this study, 
tested PCR negative for schistosome DNA from the pellets of their lavage samples. 
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None of the women were FGS PCR+ve at both study entry and study exit. No 
information of praziquantal treatment was recorded for  all women including those 
who tested positive for schistosome DNA in the pellet of their lavage samples in this 
study. 
Table 4.2: Prevalence of female genital schistosomiasis DNA 
Variables N=383 
HIV sero-converters 52/383 (13.6%) 
  
Total FGS PCR +ve 9/383 (2.35%) 
Vulindlela site 6/383 (1.57%) 
eThekwini site 3/383 (0.78%) 
FGS PCR +ve at study entry 3/9 (33%) 
FGS PCR +ve at study exit 6/9 (67%) 
FGS PCR +ve at study entry & exit 0/9 (0%) 
FGS PCR+ve that acquired HIV at study exit 4/9 (44%) 
FGS PCR+ve, HIV negative at study exit 5/9 (56%) 
  
 
4.3 DNA sequencing of amplicons and alignment to S. haematobium sequence 
Sequences of all FGS PCR positive samples showed similar homology to the S. 
haematobium control sequence, with no differences in the nucleotide sequences in 
any of the participant’s sequences for the 77 bases [Figure 4.3]. 
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Figure 4.1: Multiple alignments of FGS PCR products, validating that FGS PCR 
positive sequences showed similar nuclear base composition when compared to S. 
haematobium control sequence.  The 77-bp internal transcription spacer is 
homologous to both S. mansoni & S. haematobium species. 
4.4 Seroprevalence of schistosomiasis 
Levels of Schistosoma spp specific IgG from n= 383 female participants were 
measured at both study entry and study exit time points (Table 4.3).  
Table 4.3: Optical densities based on raw data for Schistosoma spp IgG in IgG-HIV-, 
IgG+HIV-, IgG+HIV- & IgG+HIV+ women at entry & exit of study before 
controlling for an OD >1.0. 
   
Study entry (month 
3) 
S. mansoni IgG-HIV- 
(N=362) 
S. mansoni IgG + HIV- 
(N=21) 
Median OD values 0.363 0.742 
Range OD values 0.065-0.782 0.066-1.426 
   
Study exit (month 52) S. mansoni IgG-HIV- 
(N=323) 
S. mansoni IgG+HIV- 
(N=15) 
Median OD values 0.289 0.783 
Range OD values 0.0061-0.491 0.068-1.498 
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Study exit (month 52) S. mansoni IgG-HIV+ 
(N=41) 
S. mansoni IgG+HIV+ 
(N=4) 
Median OD values 0.312 0.738 
Range OD values 0.052-0.562 0.059-1.369 
 
Of the 383 women at study entry, 21 (5.5%) had detectable S. mansoni IgG in their 
plasma samples [Figure 4.2 (A)]. At study exit, 19/383 women (5.0%) had detectable 
IgG [Figure 4.2 (B)]. Only 17 women had IgG at both time points. Of the 9 FGS 
PCR+ women (Table 4.2 above), 7 were also positive for S. mansoni IgG indicating a 
concordance between the systemic compartment and the genital tract. From the 
21/383 women that tested IgG sero-positive for S. mansoni at study entry, only 4 of 
these women had HIV sero-converted by study exit. No significant differences in the 
optical densities for the IgG titres were found between women who became HIV-
infected compared to those who remained uninfected (p=0.47) [Figure 4.2 (C)]. 
Table 4.4: S. mansoni-specific IgG sero-prevalence of women in the placebo arm of 
the CAPRISA 004 cohort. 
  
Participants S. mansoni IgG +ve at study entry 21/383 (5.5%) 
Participants remained S. mansoni IgG+ve at study exit 2/21 (9.5%) 
  
Participants S. mansoni IgG +ve at study exit 19/383 (5.0%) 
Participants S. mansoni IgG -ve at study entry 17/19 (89.5%) 
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Figure 4.2: (A) S. mansoni specific IgG levels in women at month 3 of study (study 
entry). Detectable Ab levels were found for 21/383 (5.5%) of study participants.  
Horizontal line represents cut-off Ab titres. (B) Total S. mansoni-specific IgG 
antibody titres were measured in study participants at study exit. 19/383 (5.0%) of 
women had detectable plasma Ab levels. (C) Schistosomiasis IgG titres from HIV 
uninfected S. mansoni positive women (n=34) compared to S. mansoni positive 
women who later became HIV-infected (n=4).  S. mansoni arbitrary IgG titres from 
study participants that seroconverted showed that HIV had no significant effect on 
IgG levels of study participants that were exposed to S. mansoni. 
4.5 Genital cytokine concentrations associated with FGS or HIV infection at 
study entry (month 3) 
To investigate genital tract inflammation, screening of 48 pro- and anti-inflammatory 
cytokines and chemokines of CVLs from women in the CAPRISA 004 cohort was 
conducted at study entry (month 3-Table 4.5) and at study exit (month 52 on average-
Table 4.6). In women who were FGS PCR+ significantly higher levels of MCP-3 was 
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observed compared to the FGS- women, and in contrast, FGS- women showed 
significantly higher basic FGF than in FGS+ women [figure 4.3]. 
Study Entry: Cytokine levels of women were screened at month 3 of the study in 
order to investigate their role in genital inflammation. At month 3, all women 
participating in  the CAPRISA 004 trial were all HIV negative (Table 4.5). 
Table 4.5: Cytokine concentrations amongst FGS-HIV- & FGS+HIV- women at 
study entry 
Cytokine FGS-HIV- 
Median (IQR) 
(N=380) 
[pg/ml] 
FGS+HIV- 
Median (IQR) 
(N=3) 
[pg/ml] 
P value FDR adjusted p-value 
BASIC_FGF 25.1 (18.1-31.8) 12.0 (7.2-15.3) 0.025 0.5837 
EOTAXIN 7.0 (0.9-12.9) 1.7 (0.1-4.4) 0.165 0.5837 
G-CSF 209.3 (72.1-885.2) 36.9 (5.3-782.0) 0.235 0.5837 
GM_CSF 94.3 (65.5-122.4) 51.2 (38.5-119.9) 0.183 0.5837 
IFN_G 40.9 (21.7-70.8) 47.2 (22.4-68.2) 0.875 0.9547 
IL_10 23.5 (7.3-38.3) 6.6 (0.6-11.9) 0.064 0.5837 
IL_12P70 48.0 (23.4-95.5) 11.4 (0.9-59.0) 0.105 0.5837 
IL_13 3.0 (1.6-4.7) 1.8 (0.4-3.0) 0.207 0.5837 
IL_15 2.7 (0.0-8.9) 2.6 (0.0-8.9) 0.645 0.8465 
IL_17A 17.9 (10.6-28.9) 10.7 (5.3-22.0) 0.265 0.5837 
IL_1B 38.9 (11.3-154.1) 40.9 (3.5-118.4) 0.688 0.8465 
IL_1RA 9158.2 (4989.4-13321.1) 21962.6 (1957.7-29027.6) 0.376 0.6224 
IL_2 3.2 (1.8-5.3) 3.2 (0.0-7.0) 0.844 0.9425 
IL_4 0.8 (0.5-1.3) 0.7 (0.3-0.8) 0.306 0.5870 
IL_5 0.4 (0.1-1.6) 0.4 (0.2-0.7) 0.981 0.9806 
IL_6 7.6 (3.0-20.7) 2.2 (0.5-10.9) 0.170 0.5837 
IL_7 2.8 (1.4-5.1) 1.0 (0.3-2.8) 0.107 0.5837 
IL_8 392.6 (138.7-1092.8) 129.2 (0.9-1228.3) 0.360 0.6224 
IL_9 5.7 (3.3-11.0) 2.5 (0.1-5.7) 0.105 0.5837 
IP_10 169.8 (35.7-688.1) 34.0 (7.3-833.1) 0.349 0.6224 
MCP_1 17.6 (9.0-45.3) 10.6 (2.0-51.6) 0.409 0.6298 
MIP_1A 2.1 (1.0-2.9) 0.6 (0.6-0.7) 0.052 0.5837 
MIP_1B 13.2 (5.6-31.5) 12.9 (2.3-55.0) 0.840 0.9425 
PDGF_BB 10.2 (5.7-18.5) 6.3 (0.9-12.0) 0.197 0.5837 
RANTES 9.6 (3.8-18.1) 7.0 (0.8-10.2) 0.300 0.5870 
TNF_A 10.2 (5.4-20.9) 4.7 (4.1-6.0) 0.092 0.5837 
VEGF 375.4 (175.7-761.9) 140.5 (22.7-721.4) 0.255 0.5837 
CTACK 19.6 (11.4-30.9) 31.1 (15.7-34.3) 0.394 0.6298 
GRO_A 394.0 (54.8-1509.1) 235.3 (32.1-3527.7) 0.901 0.9615 
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Table 4.5 continued 
HGF 224.1 (75.3-637.0) 105.1 (28.7-632.5) 0.536 0.7563 
IFN_A2 24.4 (17.5-35.2) 28.2 (21.6-43.9) 0.467 0.6786 
IL_12P40 345.1 (253.2-454.6) 335.8 (182.1-681.0) 0.969 0.9806 
IL_16 36.3 (18.2-79.6) 58.0 (54.1-88.3) 0.268 0.5837 
IL_18 156.4 (51.2-487.7) 260.1 (9.6-997.7) 0.964 0.9806 
IL_1A 158.1 (69.7-413.5) 99.8 (44.9-224.7) 0.420 0.6298 
IL_2RA 27.4 (16.9-44.7) 42.2 (29.9-44.3) 0.296 0.5870 
IL_3 134.1 (85.6-210.8) 147.1 (78.1-147.2) 0.712 0.8549 
LIF 19.1 (13.3-33.1) 14.7 (12.7-18.8) 0.370 0.6224 
M_CSF 84.4 (45.1-174.1) 90.8 (39.5-91.7) 0.653 0.8465 
MCP_3 13.1 (6.6-26.0) 46.7 (19.6-87.8) 0.038 0.5837 
MIF 5025.1 (963.5-10371.2) 3587.3 (169.3-10549.9) 0.679 0.8465 
MIG 597.0 (203.5-1732.6) 192.5 (128.1-616.6) 0.268 0.5837 
SCF 9.0 (3.8-19.2) 6.5 (0.0-7.3) 0.204 0.5837 
SCGF_B 146.0 (1.6-547.2) 176.2 (1.6-1180.5) 0.805 0.9425 
SDF_1A 107.3 (71.4-142.9) 139.5 (108.6-198.5) 0.198 0.5837 
TNF_B 4.9 (3.0-7.6) 3.0 (2.7-3.2) 0.148 0.5837 
TRAIL 25.5 (8.7-69.6) 33.5 (0.0-35.0) 0.627 0.8465 
B_NGF 1.1 (0.5-3.4) 0.6 (0.3-1.0) 0.226 0.5837 
Kruskal Wallis tests was performed for FGS-HIV- & FGS+HIV- study groups at study entry. Samples were not adjusted for 
STIs. Significant p values and those withstanding false discovery rate adjustment are indicated in bold text. 
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Figure 4.3: Comparison of CVL Basic-FGF and MCP-3 concentrations in FGS- 
(n=380) and FGS+ women (n=3) at study entry. Mann Whitney test was used to test 
for differences between groups. 
Th1 (IFN-γ, IP-10, IL-8 & TNF-α) and Th2 cytokines (IL-4, IL-5, IL-9 & IL-10) that 
are usually associated with helminth infection were also investigated at study entry in 
the presence or the absence of FGS as shown in table 4.5, figure 8.1 & 8.2 
(Appendix).  Women who were FGS- had a higher median of IP-10 (median 169.8 
pg/ml, IQR 35.7-688.1 pg/ml) [figure 8.1] compared to the FGS+ women (median 
34.0 pg/ml, IQR 7.3-833.1 pg/ml), with no significant difference noted. Median 
cytokine levels of IL-9 & IL-10 (median 5.7 pg/ml, IQR 3.3-11.0 pg/ml & median 
23.5 pg/ml, IQR 7.3-38.3 pg/ml) [figure 8.2] were higher in FGS- women compared 
to FGS+ women (median 2.5 pg/ml, IQR 0.1-5.7 pg/ml & median 6.6 pg/ml, IQR 0.6-
11.9 pg/ml), however no significant differences were observed. 
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4.6 Genital cytokine concentrations associated with FGS or HIV infection at 
study exit (month 52) 
To investigate genital tract inflammation, screening of 48 pro- and anti-inflammatory 
cytokines and chemokines of CVLs from women in the CAPRISA 004 cohort was 
conducted at study exit (month 52 on average-Table 4.6). 
Study Exit: Cytokine & chemokine concentrations of these women were also 
investigated at month 52 of the study in order to investigate their role in inflammation 
in the presence/absence of FGS and or with/without HIV as 52/383 (13.58%) women 
had sero-converted by study exit. 
Table 4.6: Comparison of cytokine concentrations at study exit amongst FGS-HIV-, 
FGS+HIV-, FGS-HIV+ & FGS+HIV+ study women  
Cytokine FGS-HIV- 
Median (IQR) 
(N=332) 
[pg/ml] 
FGS-HIV+ 
Median (IQR) 
(N=45) 
[pg/ml] 
FGS+HIV- 
Median (IQR) 
(N=3) 
[pg/ml] 
FGS+HIV+ 
Median (IQR) 
(N=3) 
[pg/ml] 
p-
value 
False 
Discovery 
Rate p-
value 
BASIC_FGF 25.2 (15.7-33.8) 27.3 (15.7-34.2) 16.8 (8.3-27.9) 22.1 (18.2-34.3) 0.712 0.777 
EOTAXIN 6.6 (0.9-12.7) 6.0 (0.1-14.6) 0.1 (0.1-10.1) 3.4 (0.1-14.3) 0.456 0.5842 
G-CSF 126.2  
(38.8-560.3) 
525.5 (117.2-1813.2) 150.3 
 (8.0-1629.2) 
1230.2 
(45.9-1928.1) 
*0.004 **0.0151 
GM_CSF 84.9 (55.2-109.5) 89.1 (57.4-110.6) 71.6 (46.8-
113.6) 
101.1 (83.0-119.2) 0.812 0.8664 
IFN_G 36.9 (19.8-62.2) 36.0 (20.9-69.3) 26.3 (14.5-96.3) 17.4 (16.4-112.6) 0.932 0.9317 
IL_10 18.1 (3.4-34.6) 19.4 (7.8-37.4) 14.7 (2.2-25.7) 14.0 (11.0-42.8) 0.490 0.5884 
IL_12P70 34.4 (13.2-74.5) 43.5 (21.9-87.7) 24.2 (14.6-39.6) 26.7 (23.1-97.0) 0.256 0.4551 
IL_13 2.2 (1.0-4.2) 2.8 (1.1-5.6) 1.2 (0.0-3.6) 1.5 (0.0-5.3) 0.450 0.5842 
IL_15 2.4 (0.3-7.9) 1.3 (0.3-10.7) 4.4 (0.0-4.8) 7.2 (0.0-19.7) 0.710 0.777 
IL_17A 18.1 (10.4-35.8) 23.0 (15.2-35.1) 14.5 (8.0-19.1) 24.7 (21.3-32.7) 0.372 0.5514 
IL_1B 32.3 (10.0-139.7) 137.4 (29.7-432.0) 61.3 (22.1-67.9) 45.8 (13.8-47.0) *<.001 **0.0046 
IL_1RA 7334.1 
 (3234.9-11417.5) 
11371.3  
(7025.9-17298.1) 
5928.4 (2743.3-
12737.9) 
9444.2  
(2853.0-17699.0) 
*<.001 **0.0046 
IL_2 2.7 (1.3-4.7) 3.8 (1.7-6.8) 0.9 (0.7-5.7) 3.1 (0.6-7.9) 0.378 0.5514 
IL_4 0.7 (0.5-1.2) 0.7 (0.5-1.5) 0.4 (0.3-1.5) 0.7 (0.4-1.6) 0.851 0.8693 
IL_5 0.4 (0.1-1.4) 0.8 (0.3-2.0) 0.3 (0.0-8.3) 1.1 (0.3-4.0) 0.105 0.2108 
IL_6 5.0 (2.0-19.1) 12.2 (3.3-29.6) 11.4 (1.2-45.4) 16.5 (4.3-29.8) 0.041 0.0985 
IL_7 2.4 (1.0-4.9) 2.8 (1.0-5.6) 1.4 (0.8-3.2) 3.3 (1.2-5.6) 0.462 0.5842 
IL_8 341.2  
(73.5-954.9) 
732.6 (365.5-3217.5) 320.0 
 (1.3-712.6) 
612.3 
 (125.2-935.9) 
*<.001 **0.0031 
IL_9 4.9 (2.6-8.9) 6.2 (3.7-11.0) 3.4 (0.7-5.1) 4.9 (3.5-16.3) 0.159 0.2934 
IP_10 131.1 (33.2-
781.6) 
1302.8 (161.8-3817.7) 26.4 (21.8-
138.9) 
2939.4 (58.6-
10640.2) 
*<.001 **0.0002 
MCP_1 13.6 (5.1-40.8) 17.3 (8.4-47.2) 10.4 (2.9-13.7) 14.7 (10.0-23.5) 0.481 0.5884 
MIP_1A 1.9 (0.9-2.9) 2.4 (1.1-3.3) 1.0 (0.4-3.1) 1.1 (1.1-3.3) 0.390 0.5514 
MIP_1B 10.3 (3.9-28.4) 23.6 (8.7-59.4) 5.1 (2.4-37.4) 28.6 (10.3-71.9) *0.003 **0.0151 
PDGF_BB 8.6 (4.6-17.1) 14.7 (7.0-29.1) 6.2 (2.6-19.0) 11.4 (9.9-13.4) 0.088 0.1919 
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Kruskal Wallis tests was performed for FGS-HIV, FGS-HIV+, FGS+HIV- & FGS+HIV+ study groups at study exit. Samples 
were not adjusted for STIs. Significant p values and those withstanding false discovery rate adjustment are indicated in bold text. 
* Deontes Bonferroni correction to adjust for multiple comparisons was also applied to prevent a Type 1 error and circumvents 
over estimating statistical significance. ** Denotes a p value that remained significant after false discovery rate adjustment. 
 
Women who were FGS-HIV+ had significantly higher levels of IL-1β (median 137.4 
pg/ml, IQR 29.7- 432.0 pg/ml) [figure 4.4 A] than FGS-HIV- women (median 32.3 
pg/ml, IQR 10.0-139.7 pg/ml; p<0.0001, FDR adjusted - p=0.0046). Median 
concentrations of MIF were significantly higher in FGS-HIV+ (median 6646.4 pg/ml, 
IQR 3034.4-12862.1 pg/ml) women compared to FGS-HIV- women (median 3415.9 
pg/ml, IQR 460.-8207.7 pg/ml; p=0.0014, FDR adjusted - p=0.020). The FGS-HIV+ 
women had significantly higher median cytokine levels of MIF (median 6646.4 
pg/ml, IQR 3034.4-12862.1 pg/ml) compared to FGS+HIV- women (median 1068.4 
Table 4.6 Continued       
RANTES 7.7 (3.1-18.2) 19.4 (8.6-49.8) 6.2 (1.2-7.2) 21.1 (13.8-28.7) *0.001 **0.0071 
TNF_A 9.6 (5.1-19.9) 13.1 (4.8-30.2) 4.6 (4.6-24.8) 6.8 (6.2-23.2) 0.709 0.777 
VEGF 298.3 
 (125.1-677.1) 
605.8  
(285.9-1126.8) 
263.1  
(197.4-314.9) 
289.3  
(252.6-460.9) 
*0.004 **0.0151 
CTACK 17.2 (10.1-25.9) 26.4 (14.9-36.1) 11.5 (0.4-18.3) 19.4 (17.6-36.4) *0.002 **0.0095 
GRO_A 267.4  
(43.3-1615.8) 
1083.9  
(277.6-5014.9) 
46.7  
(1.7-485.9) 
2051.1  
(44.9-37751.1) 
*<.001 **0.0052 
HGF 142.9 (51.9-
436.9) 
231.6 (127.6-763.7) 251.4 (14.1-
343.0) 
123.9 (10.8-343.9) 0.047 0.1064 
IFN_A2 21.7 (16.0-28.9) 23.0 (17.6-32.2) 18.8 (1.3-24.6) 18.0 (15.3-41.6) 0.568 0.6651 
IL_12P40 317.4 
(245.7-426.2) 
331.2 
(266.8-540.3) 
465.4 
(0.2-494.0) 
566.1 
(467.3-577.8) 
0.136 0.2607 
IL_16 37.6 (20.9-72.6) 56.8 (39.9-87.2) 40.1 (1.0-54.8) 46.3 (39.9-78.0) 0.032 0.0815 
IL_18 102.7  
(35.1-333.9) 
137.3 (71.6-462.5) 117.5  
(2.8-271.6) 
59.5 (24.4-847.7) 0.313 0.5189 
IL_1A 128.9  
(58.5-346.8) 
269.6  
(97.8-621.3) 
57.2 
(12.3-128.1) 
65.0 
(23.7-384.2) 
0.021 0.0549 
IL_2RA 25.6 (16.1-41.2) 40.4 (22.7-56.0) 30.0 (0.1-36.6) 29.5 (25.8-82.3) *0.009 **0.0257 
IL_3 114.2  
(82.0-168.4) 
150.2  
(82.4-218.7) 
120.9  
(13.3-188.7) 
102.2 
 (101.5-292.6) 
0.272 0.4658 
LIF 16.0 (10.8-27.4) 20.3 (11.4-35.4) 17.3 (0.1-34.2) 10.7 (9.1-43.8) 0.423 0.5804 
M_CSF 74.6 
 (39.4-149.3) 
116.4 (58.3-212.2) 25.2 (12.5-
125.7) 
40.9 (33.4-85.2) *0.012 **0.0336 
MCP_3 17.4 (8.5-28.5) 20.3 (11.2-29.3) 9.7 (0.2-25.7) 26.2 (19.6-33.7) 0.391 0.5514 
MIF 3415.9  
(460.0-8207.7) 
6646.4 
 (3034.4-12862.1) 
1068.4 (37.7-
2498.0) 
3723.9 
 (517.6-506541.2) 
*0.006 **0.020 
MIG 442.1  
(110.6-1734.9) 
2820.0 
 (1052.1-8028.0) 
151.0 
 (3.3-153.8) 
2838.7  
(515.7-8099.8) 
*<.001 **<0.001 
SCF 6.3 (2.7-15.1) 16.5 (9.3-26.0) 5.5 (0.0-9.6) 13.9 (6.2-43.7) *<.001 **0.0002 
SCGF_B 67.8  
(1.6-304.2) 
257.0  
(59.7-1082.6) 
204.8  
(1.6-271.6) 
389.2  
(62.8-398.3) 
*0.005 **0.0167 
SDF_1A 90.2 (54.2-141.7) 130.7 (81.0-170.1) 49.5 (5.4-108.0) 160.1 (130.1-168.0) *0.005 **0.0167 
TNF_B 4.2 (2.3-6.7) 4.6 (1.8-7.6) 2.8 (0.0-6.8) 3.4 (2.0-12.4) 0.842 0.8693 
TRAIL 23.4 (5.0-72.2) 32.5 (18.8-101.1) 35.8 (0.0-108.5) 19.5 (16.5-97.1) 0.103 0.2108 
B_NGF 0.9 (0.4-2.4) 1.4 (0.5-2.5) 1.2 (0.0-1.3) 0.4 (0.3-7.3) 0.355 0.5514 
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pg/ml, IQR 37.7-2498.0 pg/ml; p=0.034, FDR adjusted - p=0.020). Median cytokine 
levels of IL-1A were significantly higher in FGS-HIV+ (median 269.6 pg/ml, IQR 
97.8-621.3 pg/ml) women when compared to FGS-HIV- (median 128.9 pg/ml, IQR 
58.5-346.8 pg/ml; p=0.0088) and FGS+HIV- women (median 57.2 pg/ml, IQR 12.3-
128.1 pg/ml; p=0.0499). Women in the FGS-HIV+ group had significantly higher 
median cytokine levels of IL-6 (median 12.2 pg/ml, IQR 3.3-29.6 pg/ml) when 
compared to FGS-HIV- women (median 5.0 pg/ml, IQR 2.0-19.1 pg/ml; p=0.0069). 
Th2 cytokine levels of IL-1RA [figure 4.4 (C)] were significantly higher in FGS-
HIV+ (median 11371.3 pg/ml, IQR 7025.9-17298.1 pg/ml) women compared to FGS-
HIV- (median 7334.1 pg/ml, IQR 3234.9-11417.5 pg/ml) women (* p<0.0001, FDR 
adjusted - p<0.0046). Median cytokine levels of IL-2RA [figure 4.5] were 
significantly lower in FGS-HIV- (median 25.6 pg/ml, IQR 16.1-41.2 pg/ml) women 
when compared to FGS-HIV+ (median 40.4 pg/ml, IQR 22.7-56.0 pg/ml) women (* 
p=0.0012, FDR adjusted - p=0.0257).  
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Figure 4.4: Concentrations of Th1 cytokines (IL-1β, MIF, IL-1A & IL-6) investigated 
between the 4 study groups (FGS-HIV-, FGS+HIV-, FGS-HIV+ & FGS+HIV+) at 
study exit. Kruskal Wallis tests were performed amongst the four groups. Non-
parametric two tailed Mann Whitney tests were performed to test for differences 
between the FGS- and FGS+ groups. * Denotes Bonferroni correction to adjust for 
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multiple comparisons was also applied to prevent a Type 1 error and circumvents over 
estimating statistical significance (p<0.0125). ** Denotes a p value that remained 
significant after false discovery rate adjustment as depicted in Table 4.6 
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 Figure 4.5: T-helper 2 (IL-1RA & IL-2RA) cytokines investigated between the 4 
study groups (FGS-HIV-, FGS+HIV-, FGS-HIV+ & FGS+HIV+) at study exit. 
Kruskal Wallis tests were performed amongst the four groups. Non-parametric two 
tailed Mann Whitney tests were performed to test for differences between the FGS- 
and FGS+ groups. * Denotes Bonferroni correction to adjust for multiple comparisons 
was also applied to prevent a Type 1 error and circumvents over estimating statistical 
significance (p<0.0125). ** Denotes a p value that remained significant after false 
discovery rate adjustment as depicted in Table 4.6 
In addition, growth factors (G-CSF, VEGF, HGF, MCSF, CSF & SCGF-β) were also 
investigated at study exit amongst FGS-HIV-, FGS+HIV-, FGS-HIV+ & FGS+HIV+ 
groups in detail and represented in figure 4.6 & 4.7. Median levels of G-CSF (D) 
 
 
 
62 
 
were significantly higher in FGS-HIV+ (median 525.5 pg/ml, IQR 117.2-1813.2 
pg/ml) women compared to FGS-HIV- (median 126.2 pg/ml, IQR 38.8-560.3 pg/ml) 
women (* p=0.0003, FDR adjusted -  p=0.0151). Women in FGS-HIV+ study group 
had significantly higher levels of VEGF (figure 4.6) compared to FGS-HIV- women 
(* p=0.0002, FDR adjusted - p=0.0151). 
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Figure 4.6: Median cytokine levels of growth factors G-CSF, VEGF & HGF were 
compared in all 4 study groups (FGS-HIV-, FGS+HIV-, FGS-HIV+ & FGS+HIV+) at 
study exit. Kruskal Wallis test was performed amongst the 4 study groups. Non-
parametric two tailed Mann Whitney tests were performed to test for differences 
between the FGS- and FGS+ groups. *Denotes Bonferroni correction to adjust for 
multiple comparisons was also applied to prevent a Type 1 error and circumvents over 
estimating statistical significance (p<0.0125). ** denotes a p value that remained 
significant after false discovery rate adjustment as depicted in Table 4.6. 
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Median levels of HGF were also significantly higher in FGS-HIV+ women (median 
231.6 pg/ml, IQR 127.6-763.7 pg/ml) compared to FGS-HIV- women (median 142.9 
pg/ml, IQR 51.9-436.9 pg/ml) (p=0.0061). Women in FGS-HIV- group had 
significantly lower levels of M-CSF (figure 4.7) compared to FGS-HIV+ women (* 
p=0.0041, FDR adjusted - p=0.0336). Growth factor SCGF-β levels (figure 4.7) were 
significantly higher in FGS-HIV+ women compared to FGS-HIV- women 
(*p=0.0005, FDR adjusted - p=0.0167). Women in the FGS-HIV+ study group had 
significantly higher levels of SCF (figure 4.7) compared to FGS-HIV- women (* 
p<0.0001, FDR adjusted - p=0.0002) and FGS+HIV- women (* p=0.034, FDR 
adjusted - p=0.0002). 
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Figure 4.7: Median cytokine levels of growth factors MCSF, SCF & SCGF-β were 
compared in all 4 study groups (FGS-HIV-, FGS+HIV-, FGS-HIV+ & FGS+HIV+) at 
study exit. Kruskal Wallis test was performed amongst the 4 study groups. Non-
parametric two tailed Mann Whitney tests were performed to test for differences 
between the FGS- and FGS+ groups. * Denotes Bonferroni correction to adjust for 
multiple comparisons was also applied to prevent a Type 1 error and circumvents over 
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estimating statistical significance(p<0.0125). ** Denotes a p value that remained 
significant after false discovery rate adjustment as depicted in Table 4.6. 
Chemokines (IL-8, IP-10, MIP-1β, RANTES, CTACK, GRO-A, IL-16, MIG & SDF-
1A) were investigated at study exit amongst FGS-HIV-, FGS+HIV-, FGS-HIV+ & 
FGS+HIV+ study groups in detail and represented in figure 4.8 & 4.9. Median 
cytokine levels of IL-8 (figure 4.8) were significantly higher in FGS-HIV+ women 
(median 732.6 pg/ml, IQR 365.5-3217.5 pg/ml) compared to FGS-HIV- women 
(median 341.2 pg/ml, IQR 73.5-954.9 pg/ml) (* p<0.0001, FDR adjusted - p=0.0031). 
Women in FGS-HIV+ study group showed significantly higher levels of IP-10 (figure 
4.8) compared to women in the FGS-HIV- study group (* p<0.0001, FDR adjusted - 
p=0.0002) and women in the FGS+HIV- study group (* p=0.0131, FDR adjusted - 
p=0.0002). Median cytokine levels of MIP-1β (figure 4.8) were significantly higher in 
FGS-HIV+ women (median 23.6 pg/ml, IQR 8.7-59.4 pg/ml), compared to  FGS-
HIV- women(median 10.3 pg/ml, IQR 3.9-28.4 pg/ml) (* p=0.0005, FDR adjusted - 
p=0.0151).  
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Figure 4.8: Median levels of chemokines IL-8, IP-10 & MIP-1β were investigated 
and compared between all 4 study groups (FGS-HIV-, FGS+HIV-, FGS-HIV+ & 
FGS+HIV+) at study exit. Kruskal Wallis test was performed amongst the 4 study 
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groups. Non-parametric two tailed Mann Whitney tests were performed to test for 
differences between the FGS- and FGS+ groups. *Denotes Bonferroni correction to 
adjust for multiple comparisons was also applied to prevent a Type 1 error and 
circumvents over estimating statistical significance. (p<0.0125).  ** denotes a p value 
that remained significant after false discovery rate adjustment as depicted in Table 
4.6. 
Women in the FGS-HIV+ study groups had significantly higher levels of RANTES 
(figure 4.9), compared to FGS-HIV women (* p=0.0003, FDR adjusted - p=0.0071) 
and FGS+HIV- women (* p=0.0343, FDR adjusted - p=0.0071). Median cytokine 
levels of CTACK (figure 4.9) were significantly higher in FGS-HIV+ women 
(median 26.4 pg/ml, IQR 14.9-36.1 pg/ml), compared to FGS-HIV- women(median 
17.2 pg/ml, IQR 10.1-25.9 pg/ml) (* p=0.0004, FDR adjusted -p=0.0095) and 
FGS+HIV- women (* p=0.043, FDR adjusted -p=0.0095). Women in the FGS-HIV+ 
study group had significantly higher median cytokine levels of GRO-A (figure 4.9), 
compared to women in the FGS-HIV- study group (* p=0.0001, FDR p=0.0052) and 
FGS+HIV- women (* p=0.0431, FDR adjusted - p=0.0052).  
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Figure 4.9: Median levels of chemokines RANTES, CTACK & GRO-A were 
investigated and compared between all 4 study groups (FGS-HIV-, FGS+HIV-, FGS-
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HIV+ & FGS+HIV+) at study exit. Kruskal Wallis test was performed amongst the 4 
study groups. Non-parametric two tailed Mann Whitney tests were performed to test 
for differences between the FGS- and FGS+ groups. *Denotes Bonferroni correction 
to adjust for multiple comparisons was also applied to prevent a Type 1 error and 
circumvents over estimating statistical significance (p<0.0125). ** denotes a p value 
that remained significant after false discovery rate adjustment as depicted in Table 
4.6. 
Median cytokine levels of IL-16 (figure 4.10) were significantly higher in FGS-HIV+ 
women (p=0.0048- median 56.8 pg/ml, IQR 39.9-87.2 pg/ml) compared to FGS-HIV- 
women (median 37.6 pg/ml, IQR 20.9-72.6 pg/ml). Women in FGS-HIV+ study 
groups had significantly higher levels of MIG (median 2820 pg/ml, IQR 1052.1-
8028.0 pg/ml) (figure 4.10 )when compared to FGS-HIV- (median 442.1 pg/ml, IQR 
110.6-1734.9 pg/ml) women (* p<0.0001, FDR p<0.001) and FGS+HIV- (median 
151 pg/ml, IQR 3.3-153.8 pg/ml) women (* p=0.0018, FDR adjusted - p<0.001). 
Women in FGS-HIV+ study groups had significantly higher levels of SDF-1A (figure 
4.10) when compared to FGS-HIV- women (* p=0.0038, FDR adjusted - p=0.0167) 
and FGS+HIV- women (* p=0.0428, FDR adjusted - p=0.0167). 
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Figure 4.10: Median levels of chemokines IL-16, MIG & SDF-1A were investigated 
and compared between all 4 study groups (FGS-HIV-, FGS+HIV-, FGS-HIV+ & 
FGS+HIV+) at study exit. Kruskal Wallis test was performed amongst the 4 study 
groups. Non-parametric two tailed Mann Whitney tests were performed to test for 
differences between the FGS- and FGS+ groups. * Denotes Bonferroni correction to 
adjust for multiple comparisons was also applied to prevent a Type 1 error and 
circumvents over estimating statistical significance (p<0.0125). ** Denotes a p value 
that remained significant after false discovery rate adjustment as depicted in Table 
4.6. 
In addition to significant comparisons represented in the above tables 4.5 & 4.6, the 
following cytokines  IFN-γ, IP-10, IL-8, TNF-α, IL-4, IL-5, IL-9 and IL-10 were 
investigated at study exit between FGS- and FGS + study groups [Figure 4.11 (A-F) ] 
in further detail, due to their associations with helminth infections (Adachi et al., 
2014). The Th1 & Th2 cytokines were investigated without HIV as a variable, as 
represented in figure 4.11 (A-C). FGS+ women had higher levels of IL-6 – [figure 
4.11 (A)] compared to FGS- women (p=0.386), however the difference was not 
significant. Median cytokine levels of MIF – [figure 4.11(A)] showed that FGS+ 
(median 1783.1 pg/ml, IQR 37.7-506541.2 pg/ml) women had lower levels compared 
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to FGS- (median 3819 pg/ml, IQR 460.0-12862.1 pg/ml) women (p=0.485), with no 
significant difference observed. No further significant differences were observed in 
the analyses as shown in figures 4.11 (A-C). 
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Figure 4.11 (A-B): Median levels of Th1 (IL-1β, MIF, IL-6, IL-1α) cytokines (A) and 
IFN-γ, IP-10, IL-8 & TNF-α (B)  in FGS- women were compared to FGS+ women at 
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study exit. Non-parametric two tailed Mann Whitney tests were performed between 
the FGS- and FGS+ groups. 
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Figure 4.11 (C-D): Median levels of Th2 (IL-1-RA, IL-2RA, IL-4, IL-5, IL-9 & IL-
10) cytokines (C) and growth factors G-CSF, VEGF, HGF, CSF, MCSF & SCGF-β 
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(D) in FGS- women were compared to FGS+ women at study exit. Non-parametric 
two tailed Mann Whitney tests were performed between the FGS- and FGS+ groups.  
Growth factors & chemokines shown in figure 4.11 (D-F) were also investigated in 
FGS- and FGS+ study groups without HIV as a variable. Women that were FGS+ had 
higher median levels of G-CSF (median 690.23 pg/ml, IQR 8.0-1928.1) [figure 4.11 
(D)] compared to FGS- women (median 145.44 pg/ml, IQR 38.8-1813.2 pg/ml) 
(p=0.63), with no significant difference observed. Median cytokine levels of SCGF-β 
was also higher in FGS+ (median 238.18 pg/ml, IQR 1.6-398.3 pg/ml) women 
compared to FGS- (median 84.4 pg/ml, IQR 1.6-1082.6 pg/ml) women (p=0.5), 
however this trend observed was not a significant difference. No significant 
differences were observed between FGS- and FGS+ study groups in the below figures 
4.11 (D-F) 
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Figure 4.11 (E-F): Median cytokine levels of chemokines IL-8, MIP-1β, RANTES, 
CTACK, GRO-A, IL-16, MIG & SDF-1A were investigated in FGS- and FGS+ study 
groups at study exit. No significant differences were observed between study groups. 
Statistical analysis was performed using the Mann Whitney tests between study 
groups.  
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In this study, of the 383 women, 38 were positive for the S mansoni IgGs similar 
levels of IgG were found between the women that had HIV seroconverted compared 
to the HIV negative women. Only 9 of the 383 women had any evidence of FGS in 
their genital tracts. At study entry, of the 48 soluble proteins which included 
cytokines, chemokines and growth factors, only MCP-3, a chemokine was 
significantly higher in women in the presence of FGS compared to women without 
FGS. Furthermore, at study exit, in FGS+HIV+ compared to FGS+HIV- women, no 
differences were found in their genital tract cytokine profiles, which could be due to 
the low sample sizes for each group. However when the overall HIV-infection status 
was taken into account at study exit and in the absence of FGS, increased cytokine 
profiles, were predominant with HIV infection. These data indicate that HIV was 
primarily driving immune activation, which was evident in the female genital tract. 
The HIV-infected group displayed a mixture of consistently higher levels of Th1, Th2 
responses, chemokines & growth factors compared with the HIV negative group. 
These data further point to the complexity of immune responses that prevail in the 
face of helminth infections that may pose additional risk for HIV acquistion and 
further impacts public health. 
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Chapter 5: Discussion 
The prevalence of Schistosoma parasites worldwide and particularly in sub-Saharan 
Africa and southern Africa, together with the disease and pathogenesis including 
genital schistosomiasis following parastic infection, places a significant burden on 
public health. In addition the high incidence and prevalence of HIV-infection in sub-
Saharan and southern Africa compounds the disease burden in these afflicted 
populations, and further highlights the public health challenges faced in these regions. 
The interplay between these two diseases- schistosomiasis and HIV- remains poorly 
understood. 
The focus of this study was to investigate the relationship between FGS and risk for 
HIV-acquisition. FGS is a manifestation of the Schistosoma parasite that is often 
overlooked, and largely underdiagnosed particularly in early childhood and young 
adulthood [reviewed in (Bustinduy et al., 2014)]. The presence of FGS which is 
associated with increased immune responses in the genital tract may predispose 
women to HIV infection, and one of the mechanisms for increased HIV infection risk 
is through of lesions in the genital tract (Kleppa et al., 2014). Lesions in the mucosa 
surrounding the schistosomal eggs in situ create a breach in the genital tissue which 
may also be a crucial site for HIV-entry [reviewed in (Kjetland et al., 2012)] and may 
likely also facilitate the transmission of HIV-1 to their sexual partners [reviewed in 
(Mbabazi et al., 2011)].  
Female genital schistosomiasis PCR positive samples are usually associated with the 
presence of S. haematobium ova in the tissue of the female genital tract (Kjetland et 
al., 2009), which is usually confirmed by colposcopy. It has been found that not all 
women who test positive for schistosome DNA in the pellet of CVL samples have 
FGS and not all women with clinical evidence of FGS through colposcopy test 
positive for schistosome DNA in their lavage pellets (Kjetland et al., 2009).  In 
clinical practice it was reported that cervix, the fallopian tubes and the vagina 
commonly show S. haematobium ova (Arean, 1956, Badawy, 1962, Friedberg et al., 
1991). Autopsy specimens of the genital tract also revealed ova in the ovaries and the 
uterus as well (Al-Adnani and Saleh, 1982, Friedberg et al., 1991, Gelfand and Ross, 
1953, Swai et al., 2006). These findings may indicate that FGS may be grossly under-
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diagnosed and reported in clinical practice if all areas of the female genital tract are 
not thoroughly examined.  
Apart from colposcopic examination, which remains the gold standard for the 
diagnosis of FGS, PCR in vaginal lavage samples of women is a suitable alternative 
(Kjetland et al., 2009). Female genital schistosomiasis PCR however may be quite 
limiting due to calcified eggs in the genital tract which would contain degraded DNA 
that is unable to amplify, resulting in many false negatives. The need for an internal 
positive control is warranted in order to distinguish a PCR negative result from PCR 
inhibition. Detection of FGS using PCR can be a useful tool in diagnostics and could 
supplement gynaecological examinations (Kjetland et al., 2009), and act as a further 
confirmatory tool. 
In this study, real-time PCR screening yielded a relatively low prevalence of FGS 
(2.3%) in women from both the urban and rural sites (Ethikwini and Vulindlela). 
These data may underestimate true prevalence of female genital tract schistosomiasis, 
as some of the Schistosoma eggs may calcify in situ (Cheever et al., 1975) and 
therefore give false negative DNA results.  Additionally, prior studies have shown 
that within 2-6 months of praziquantel treatment, resolution of these lesions occurred 
(Kjetland et al., 2008, Silva et al., 2005), however, long after puberty, the effects of 
schistosomiasis may still be seen (King and Dangerfield-Cha, 2008, Kjetland et al., 
2008).   
This data suggests that FGS is not common in both rural and urban CAPRISA 004 
settings. More women from rural KwaZulu-Natal had FGS than the urban setting. 
However, due to the small sample size of women who tested positive for FGS DNA, 
the ability to reliably determine the differences in the prevalence rates of FGS in the 
rural and urban settings are limited and will need to be confirmed in a larger study. In 
addition to a small number of women who tested positive for FGS DNA, no women 
had FGS DNA detected at both study entry and study exit and this limitation could be 
due to the PCR only being able to detect ~67% of Schistosome DNA in the genital 
tract specimens (Kjetland et al., 2009).  Another limitation of this study was the lack 
of data regarding the places where the participants resided during their childhoods and 
place of origin before living at the respective sites, as this may provide further insight 
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into specific areas where young women and children may be particularly vulnerable 
to schistosomal infections.  
This risk that FGS poses to acquiring HIV-infection remains a gap and is not fully 
understood. The data from this study shows that in women with FGS, 44% had 
acquired HIV infection by study exit and were over four times more likely to be HIV-
infected than the FGS- group. This data suggests that the presence of FGS in these 
women may have predisposed them to HIV infection. A possible mechanism for 
increased risk for HIV acquisition with co-existing FGS is that there is increased 
immune responses resulting in inflammation and granuloma formation in situ where 
the eggs are situated, which can lead to extensive tissue damage including scarring 
and fibrosis (Cheever et al., 2000, Kameh et al., 2004), including calcification which 
ultimately leads to compromised mucosal tissue integrity. Other studies have also 
suggested that FGS may facilitate the transmission of HIV (Helling-Giese et al., 1996, 
Kameh et al., 2004, Kjetland et al., 2005, Poggensee et al., 1998, Ross et al., 2002).  
The presence of schistosome DNA, due to egg excretion by S. haematobium is mostly 
found in younger women and in some cases is undetectable in older women as the 
eggs tend to calcify [(Kjetland et al., 2009), reviewed in (Kjetland et al., 2012)]. As a 
result, these calcified lesions are less likely to elicit strong immune responses. Many 
FGS PCR positives may not have been detected due to the calcification of the ova in 
the genital tissue, indicating non-viable or dead ova. The calcified ova which is 
foreign antigen, however, can still stimulate the immune system through the induction 
and influx of immune cells, and this can the lead to oedema and blood vessel 
proliferation (Jourdan et al., 2011a, Jourdan et al., 2011b, Kjetland et al., 2008, 
Mbabazi et al., 2011, Silva et al., 2005).  
Immune reactions to S. haematobium eggs occur at the different phases (Jenkins et al., 
2005). The accompanying immune reactions vary during the different phases which 
could then  impact treatment success using praziquantel, the current standard 
treatment for Schistosoma infections, and this could have implications on for 
treatment success and disease resolution (Rujeni et al., 2012). However, exposure to 
this parasite generally produces a strong antibody response.  Seroprevalence rates of 
schistsomiasis, ranging as high as between 71 to 100% from Limpopo to KZN, have 
been previously recorded (Moodley et al., 2003) indicating that these areas are 
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hotspots and highly endemic for this particular parasite. The relatively low 
seroprevalence of schistosoma, of approximately 5% in our cohort study, may 
indicate that these areas may not be hotspots. The data from this study may be 
confounded by the fact that demographic data pertaining to where the participants 
were born and lived, prior to being in the Vulindlela and eThekwini sites were lacking 
and data regarding previous praziquantel treatment was not collected. Another factor 
that may have confounded seroprevalence rates in this and other studies was the 
possibility of cross reactivity to other nematode species (Mkhize-Kwitshana et al., 
2011). This may undermine the accuracy of epidemiological studies looking at 
prevalence of this parasite based on ELISA antibody testing.   
The seroprevalence does not give an indication of how acute or chronic the 
Schistosoma infection is, but merely gives a signal of exposure to the parasite (Bentz 
et al., 2003). Pathogen specific antibodies can be detected by ELISA up to 8 years 
post-infection (Murray et al., 2013).  Further methods of diagnosis, apart from 
symptoms associated with the parasite, include stool and urinal analysis for 
confirmation of the Schistosoma eggs. The prevalence data suggests that S. mansoni 
exposure or infection was not common in these women.  Additionally, in the women 
that tested positive for the Schistosoma antibody, a potential for antibody cross-
reactivity with other nematode species may also influence the data on seroprevalence 
of Schistosoma (Mkhize-Kwitshana et al., 2011). Systemic IgG levels that were 
specific for Schistosoma spp may therefore be a combination of exposure to 
schistosomiasis itself, or other helminth infections making ELISA or antibody based 
testing less robust, and reliable. 
Seven of the 9 women (78%) who were FGS PCR positive, also had detectable levels 
of S. mansoni specific IgG. This correspondence between the two detection methods 
used in this study may suggest that these women were very likely exposed to the 
Schistosoma species and indicates that two tests may be needed to confirm the 
presence of Schistosoma infection in the genital tract in the absence of a colposcopy 
of the genital tract. 
From the 21 women who had detectable levels of IgG at study entry, only 2 remained 
antibody positive throughout the study with persistently detectable levels of S. 
mansoni specific IgG at study exit. This data suggests that 90% of the women that had 
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been positive for S. mansoni specific IgG in their blood at study entry had 
undetectable levels of S. mansoni specific IgG by study exit. The decreased detection 
of sero positivity may be combination of the limitation of the assay, and the stringent 
optical density of 1.0 to detect the presence of the schistsoma specific IgG and the 
degradation of the IgG sample over time. Additionally, antigen cross-reactivity 
between parasites could possibly be the reason for such a trend to have occurred 
(Mkhize-Kwitshana et al., 2011). At study exit, a total of 19 women had detectable 
levels of S. mansoni specific IgG, however 17/19 (89%) of these women were 
antibody negative at study entry. These data may suggest that these 17 women had 
been exposed to schistosomiasis after their study entry visit, or that there was some 
degree of cross reactivity of IgGs to other nematodes, helminth proteins, worm 
species or environmental allergens (Santiago Hda et al., 2015). 
Schistosomiasis is thought to impair immune responses to other diseases and viruses 
including HIV (Chen et al., 2012). However, in this study women who became HIV 
infected later in the study had higher titres of S. mansoni specific IgG compared to 
HIV uninfected women with detectable levels of S. mansoni specific IgG, although 
these titres were not significantly different between the groups. HIV infection itself 
induces an autoimmune like condition (Weyand and Goronzy, 1992, Zandman-
Goddard and Shoenfeld, 2002) in the HIV-infected individuals, so, it may be highly 
likely that during HIV-infection, there may be a concommitant increase in antibody 
titres in people co-infected with parasites which leads to an overall higher antibody 
response. The study sample size however, precluded the ability to test whether there 
was a significant difference in the titres of the antibodies specific for the Schistosoma 
species between the groups. A larger sample size in each study group would therefore 
be more robust in assessing whether there are any significant differences in S. 
mansoni IgG titres in HIV positive women compared to HIV negative women.   
Schistosomiasis, along with other helminth infections are known to induce a Th2 anti-
inflammatory response (Adachi et al., 2014, Arnon, 1990, Coutinho et al., 2007, 
Kameh et al., 2004). Presence of both Th1 and Th2 cytokines occurs in the early 
phases of infection, with the Th2 or anti-inflammatory cytokine response dominating 
after oviposition (Adachi et al., 2014).  
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Screening for these biomarkers of genital inflammation in CVL could provide us 
further understanding into the profiles of cytokines induced due to FGS infection. 
Cytokines such as IL-4, IL-5, IL-9 and IL-13 are generally associated with 
Schistosoma infections (Silveira-Lemos et al., 2013). A previous study also screened 
for IFN-γ, IP-10, IL-8, TNF-α, IL-4, IL-5, IL-9 and IL-10, and confirmed that both 
the pro-and anti-inflammatory cytokines are associated with Schistosoma infections 
(Adachi et al., 2014, Wynn, 2015). 
This study found that healthy women who were FGS- showed to have higher cytokine 
levels of basic FGF compared to women that were FGS+ at study entry. Basic 
fibroblastic growth factor (FGF) is known for its role in angiogenesis by being 
activated upon wound healing of normal epithelial tissue (Montesano et al., 1986). 
Women who are FGS+ are most likely to have smooth epithelial tissue damage 
[reviewed in (Kjetland et al., 2012)]. The trend in this study does not correlate with 
those of literature as women who are FGS+ would be expected to have higher 
cytokine levels of basic FGF than women who are FGS-.  
Smooth epithelial tissue damage caused by inflammation can lead to the recruitment 
of immune cells to the site of infection (Helming, 2011). Monocyte chemotactic 
protein-3 (MCP-3) is a purified and cloned chemokine that is responsible for 
activating monocytes, basophils, eosinophils and T lymphocytes (Xu et al., 1995). 
The production of MCP in response to schistosome eggs has been observed as well as 
its involvement in Th2 immune responses (Chensue et al., 1995). This study showed 
that women that were FGS+ at study entry had higher levels of MCP-3 compared to 
FGS- women. Vaginal epithelial tissue damage caused by FGS may have possibly 
contributed to the activation of monocytes, eosinophils, T lymphocytes and basophils 
leading to increased MCP-3 levels in these women. 
During helminth infection, Th1 responses are usually observed first before Th2 
responses dominate (Smith et al., 2012). Th1 cytokines are generally known to 
enhance killing of intra-cellular parasites by inducing pro-inflammatory immune 
responses (Berger, 2000). IFN-γ is a Th1 cytokine that is usually produced by NK 
cells, and is one of the first innate immune responses to a foreign antigen (Bao et al., 
2014). Increased levels of IFN-γ in the genital tract may indicate a presence of 
Schistosoma eggs in the genital tract. This may then also account for the increase in 
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IFN-γ production leading to the inflammatory signature in the genital tract, which 
attracts various immune cells to the site of infection. IFN-γ attracts and increases 
cytotoxic activity of both T cells and macrophages [reviewed in (Arango Duque and 
Descoteaux, 2014)], promoting genital inflammation. Pro-inflammatory cytokines 
such as IFN-γ, IP-10, IL-8 and TNF-α were further interrogated at study entry in this 
study between FGS+ and FGS- study groups, however no significant differences were 
found between the study groups. A larger study group number for FGS infected 
individuals could help suggest that Th1 cytokines maybe higher in FGS infected 
individuals. 
Helminth infections are also known to modulate Th2 immune responses (Adachi et 
al., 2014).  In early phases of infection, Th1 immune responses are present whilst Th2 
immune responses are known to have a significant increase over the Th1 responses 
after oviposition (Adachi et al., 2014).  Infection with parasites such as the 
Schistosoma species usually result in the production of Th2 cytokines IL-4, IL-5, IL-9 
and IL-13 [reviewed in (Wynn, 2015)] which are generally classed as anti-
inflammatory cytokines that play a role in regulating inflammatory cytokines. 
In this study, IL-4 was found to be similar irrespective of the presence of FGS. IL-4 
has been known to stimulate production of IgE which plays a role in protection 
against re-infection (Medhat et al., 1998). However, measurement of IgE was not 
performed in this study. IL-9, which has been known for its pleiotropic activity in 
vivo, leads to Th2 cytokine dominating responses (Fallon et al., 2000). In this study 
however, the levels of IL-9 were similar in all of the study sub-groups. Usually an 
increase in IL-5 production leads to eosinophilia (Huang et al., 2015), as this is the 
chemoattractant for eosinophils homing to the location of parasites, their larvae or 
eggs. It is not conclusive that the women with FGS in this study had elevated levels of 
eosinophils as this test was not performed during the routine follow-up visits, and this 
is a limitation of the study. Eosinophilia usually leads to scarring and formation of 
micro-lesions of the vaginal mucosae through enzyme-directed degradation of the 
parasite infected or affected tissue (Ramarokoto et al., 2014). Genital scarring and 
lesions in the vaginal mucosae may facilitate the movement of HIV across the 
mucosal barrier [reviewed in (Shattock and Moore, 2003)]. Levels of IL-10 are 
usually expected to be elevated in schistosomal infections (Turner et al., 2013), as this 
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regulatory Th2 cytokine underlies both defence to helminth infections as well as 
atopic diseases like allergic conditions, asthma etc (Grant et al., 2011). In this study, 
further investigation of anti-inflammatory cytokines (IL-4, IL-5, IL-9, IL-10 and IL-
13) between FGS + and FGS- study groups at study entry showed that no significant 
differences were observed. The limited sample size for the FGS+ group limited the 
ability to detect meaningful differences between the groups and draw firmer 
conclusions for the roles of anti-inflammatory cytokines in the presence of FGS. 
Genital inflammation has been identified as a correlate of risk for HIV-acquisition 
(Masson et al., 2015). Masson et al., (2015) showed that women with genital 
inflammation, defined as having 5 of 9 key pro-inflammatory cytokines (MIP-1α, 
MIP-1β, IP-10, IL-8, MCP-1, IL-1α, IL-1β, IL-6, and TNF-α) elevated in the genital 
tract, had >3 fold increased HIV risk compared to women who did not have genital 
inflammation. Similarly, in this study we found that women that tested positive for 
Schistosome DNA in the genital tract samples, had a 4-fold increased risk for HIV 
acquisition than women who tested negative for schistosome DNA. Together, these 
studies highlight that both genital tract inflammation and the presence of parasitic 
DNA in the female genital tract could increase the risk for HIV infection. In addition, 
in this study, women that were FGS-HIV+ also had higher levels of pro-inflammatory 
cytokines when compared to FGS-HIV- women. A study showed that in individuals 
infected with HIV, the immune system is affected in many ways leading to both  
increases and decreases in cytokine level production [reviewed in (Breen, 2002)]. Pro-
inflammatory cytokines act as mediators of immunity in individuals infected with 
HIV (Connolly et al., 2005). This study showed that FGS-HIV+ study participants 
had higher levels of pro-inflammatory cytokines (IL-1β, MIF, IL-1α and IL-6) 
compared to FGS-HIV- women. This trend suggests that HIV in itself has an 
inflammatory effect leading to the increased production of these Th1 immune 
responses in study participants. Schistosomiasis has been hypothesized to increase 
HIV susceptibility through chronic immune modulation (Secor et al., 2003). Both pro-
inflammatory & anti-inflammatory cytokines were similar between FGS+HIV+ and 
FGS-HIV+ study groups, with no significant differences observed at study exit. The 
data suggests that, female genital schistosomiasis with HIV co-infection modulates 
the effect of Th1 & Th2 immune responses.  
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IL-1Ra has been shown to be produced during HIV infection (Zavala et al., 1995). 
This Th2 cytokine is important in balancing and controlling the inflammatory process 
of HIV infection (Zavala et al., 1995).  This study showed that FGS-HIV+ women 
had significantly higher levels of IL-1Ra & IL-2Ra when compared to FGS-HIV- 
women at study exit. This observation suggests that HIV infection may be responsible 
for the significant production of these Th2 associated cytokines that may counteract 
the inflammatory actions of HIV infection. Anti-inflammatory cytokine IL-10 also 
has the ability to act as a B-cell stimulatory factor which in some conditions can 
suppress HIV replication [reviewed in (Breen, 2002)], however cytokine levels of IL-
10 were not significantly different amongst any of the study groups at study exit.  
Growth factors involved in cellular growth, healing and proliferation, can also act as 
signalling molecules between cells (Vander Heiden et al., 2001). Cell proliferation is 
a necessary to replenish cells that have been lost through cell death (Gutierrez, 2005). 
Proliferation of cells has also been observed in HIV (Ribeiro et al., 2002). In this 
study, concentrations of growth factors (G-CSF, VEGF, HGF, MCSF, CSF and 
SCGF) were significantly higher in FGS-HIV+ women compared to FGS-HIV- 
women at study exit. This data suggests that HIV may have contributed to the higher 
levels of growth factors in HIV infected individuals which may be indicative of global 
dysregulation of soluble growth factors in HIV infection. No significant differences of 
growth factors were observed in in the small groups of FGS+HIV+ women compared 
to FGS+HIV- women, indicating that the presence of FGS alone is unlikely modulate 
these factors. 
Chemokines are cytokines or signalling proteins that have the ability to induce the 
recruitment of nearby responsive cells to the site of infection through chemotaxis 
(Turner et al., 2014). Release of chemokines are observed in early phases of HIV 
infection [reviewed in (Suresh and Wanchu, 2006). IL-8 is known to play a key role 
in recruiting neutrophils to the site of infection (Craig et al., 2009). In this study, 
FGS-HIV+ women had significantly higher levels of chemokines (IL-8, IP-10, MIP-
1β, RANTES, CTACK, GRO-A, IL-16, MIG and SDF-1A) when compared to FGS-
HIV- women at study exit. This observation suggests that based on FGS-HIV+ 
women having significantly higher levels of IL-8 and other respective chemokines 
mentioned above compared to FGS-HIV- women, that HIV infected patients could 
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also have higher levels of neutrophils, however in the absence of the neutrophil 
counts and data in this cohort, the overall high immune activation may be attributed to 
the presence of HIV infection itself. Chemokines usually dictate the intensity of 
inflammatory response against egg antigen in schistoma infected patients through 
recruitment of various immune cells (Qiu et al., 2001). No significant differences of 
chemokine levels were observed in FGS+HIV+ women when compared to FGS-
HIV+ women.  
Cytokines that showed significant differences between study groups in addition to 
cytokines that are usually associated with FGS infection (IL-1β, MIF, IL-6, IL-1α, 
IFN-γ, IP-10, IL-8, TNF-α, IL-1-RA, IL-2RA, IL-4, IL-5, IL-9 and IL-10) were also 
compared between FGS+ and FGS- women at study exit, without HIV as a variable. 
However, no significant differences in either the Th1, Th2, chemokines or growth 
factors were observed at study exit. Th2-dominant systemic responses are expected to 
be elevated in individuals burdened with helminth infection (Adachi et al., 2014, 
Grant et al., 2011, Turner et al., 2013). Owing to compartment differences, the foci of 
infection – the signature of cytokines in the genital tracts for the women who tested 
FGS+ may be different compared to signature of cytokines  in the systemic in 
response to Schistosoma spp infection and warrants further study.  
Both pro and anti-inflammatory cytokines may have played a crucial role in driving 
various immune responses caused by Schistosoma infections both systemically and 
locally (FGS) in the genital tract. However, due to the limitation that the sampling 
time was different to the time women were infected with schistsoma, likely impacts 
on our ability to accurately detect the cytokine milieu associated with acute infection 
with this helminth both locally and systemiocally. The mixture of Th1 and Th2-
immune responses in the vaginal tract may partly explain the increased likelihood of 
acquiring HIV in the presence of FGS. The ability to detect more cases of women 
with FGS by means of real-time PCR in this study may have been limited due to the 
fact that many true positives could have not been detected in older woman due to 
calcification of ova. The DNA in calcified ova may have degraded and therefore was 
unable to amplify in the real-time PCR reactions. Further study using digital PCR 
could extend the existing limits of real-time PCR and could aid in the detection of 
parasitic DNA in CVL pellets at low copy numbers. Cross reactivity of IgG responses 
 
 
 
83 
 
to other helminth infections could also have impacted on IgG responses in the S. 
mansoni specific IgG ELISAs. Antibody screening with higher specificity needs to be 
performed in order to eliminate the probability of antibody cross-reactivity between 
nematode and trematode species. 
Further investigation of these biomarkers of genital inflammation in a larger number 
of individuals may aid in understanding the role of these biomarkers in driving and 
promoting inflammation and predisposing women to HIV acquisition. In addition, 
understanding the role of Schistosoma and other parasite infections, profiling in 
parallel, the systemic and local genital compartment immune responses and cytokines, 
may better inform understanding of the risks that parasitic infections pose for HIV-
acquisition in areas of high HIV endemicity such as KwaZulu-Natal. 
This study in conclusion has established an in house PCR detection of FGS DNA in 
South African women. In this study, the low prevalence of both parasitic DNA from 
CVL pellets and low plasma IgG observed suggests that FGS and in general 
Schistosoma exposure are not common at these study sites in KZN. However, despite 
the small number of women who tested FGS+ in this study, there was still a 
significant risk of HIV acquisition indicating that the presence of FGS DNA in the 
genital tract may indeed be a risk factor for HIV acquisition as previously 
hypothesized. Other co-factors such as bacterial vaginosis and sexually transmitted 
diseases are known to be strongly associated with HIV acquisition risk through 
altering the pro-inflammatory cytokine profile in the genital tract. Despite low 
prevalence, women with FGS did have some signatures of genital tract inflammation. 
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Chapter 6: Conclusion 
Data from this study underscores the importance of understanding the immunological 
mechanisms and risk factors for HIV acquisition in regions endemic for parasitic 
infections such as Schistosoma spp and infectious diseases namely HIV. Although the 
seroprevalence of schistosomiasis and FGS in the two sites, under study, namely 
Vulindlela and eThekwini in KwaZulu-Natal (KZN) was low, large-scale studies 
testing for the presence of these parasites in the regions of high HIV prevalence is 
warranted. Combining both colposcopy, and DNA PCR for the diagnosis of FGS may 
be a valuable tool especially in high prevalence regions for both diseases in order to 
better diagnose and further unravel the exact mechanism/s by which for example a 
parasitic infection in the genital tract may be increasing the risk for a sexually 
transmitted infection like HIV. Genital tract inflammation on its own or secondary to 
bacterial vaginosis and other STDs which results in activated CD4 T cells in the 
genital mucosae are mechanisms that have been previously described, however, there 
is a paucity of data available, as to the exact mechanism by which parasites can 
mediate such risk for HIV acquisition. Genital cytokine data from this study showed 
that the presence of FGS resulted in MCP-3, a monocyte chemoattractant protein, 
being elevated. The small number of women that were positive for the presence of 
parasitic DNA in the genital tract, may have undermined the ability to detect 
differences in levels of genital cytokines that may have been increased in the presence 
of Schistosoma spp. In the women that did seroconvert, a dysregulation was seen in 
the genital cytokine profile, which may indicate that HIV in itself drives these 
responses through increased immune activation which are found locally also in the 
genital tract. This study does corroborate findings in other studies for significant risk 
of HIV acquisition, with a 4.0 times likelihood of acquiring HIV in the presence of 
FGS, despite the small number or women with FGS. Future studies aimed at using 
combination of diagnostic tools and widescale treatment at public health level for 
schistosomiasis should be evaluated in an effort to minimize the risk for HIV 
acquisition in women. Taken together, this study provides further insight into the 
complexity of ensuing immune responses in the genital tract environment in the 
presence of parasitic involvement leading to genital inflammation underscoring the 
need to further study FGS in settings where HIV and schistosomiasis converge.  
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Figure 8.1-8.2: Comparison of Th1 (8.1) and Th2 (8.2) cytokine concentrationss in 
FGS- women were compared to FGS+ women. Mann Whitney test was performed to 
test for differences between the FGS- and FGS+ groups. 
 
Table 8.1: Conventional FGS PCR reaction volumes 
Master mix reagents Master Mix for 1X Master Mix for 12X 
H2O 17.4μl 208.8μl 
Ssp48F   (5pmol/μl) 0.25μl 3μl 
Ssp124R (5pmol/μl) 0.25μl 3μl 
10X PCR Buffer 2.5μl 30μl 
Platinum Taq 0.1μl 1.2μl 
dNTP  (10mM) 0.5μl 6μl 
MgCl2  (50mM) 1μl 12μl 
DNA template 3μl  
Total volume 25μl  
 
Table 8.2: Cycling conditions of conventional FGS PCR 
Temperature (
o
C) Time  # cycles 
94 5 min   
95 30 sec 
55 60 30 sec 
72 30 sec 
72 5min   
4 ∞   
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ELISA solutions and buffers: 
 
ELISA Buffers : Carbonate Coating Buffer  
 1.6g Na2CO3 (15mM)  
2.9g NaHCO3 (35mM)  
4.2g NaCl (71mM)  Make up to 1L with ddH2O; adjust to pH 9.5 with 1M Citric 
Acid Filter sterilize and store at 4 ̊ C   
  
Blocking Buffer – 2% 
 20g Elite Fat Free Powdered milk  
 1L 1X PBS   
Dissolve powder milk in 1L 1X PBS. Store at 4°C.   
  
Dilution Buffer  1% BSA PBS 
10g Bovine Serum Albumin (BSA)  
1L 1X PBS  
Dissolve BSA in 1L 1X PBS. Store at 4°C.  
 
Substrate Buffer (for Alkaline Phosphatase) 
0.2g NaN3  
97ml Diethanolamine  
0.8g MgCl2·6H2O  Dissolve all dry compounds in 900ml ddH2O and add the 
liquified diethanolamine; adjust pH. Add ddH2O to 1L. Store at 4°C.  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20X Wash Buffer  
20g KCl  
20g KH2HPO4·2H2O  
880g NaCl  
50ml Tween-20  
100ml 10% NaN3 
Dry compounds dissolved in 4500ml ddH2O, and then added Tween-20 and 
10%NaN3.  
Add ddH2O to 5L.  
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